Document:

<PAGE>
NOTE: Information in this document marked with an "[*]" has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                                                   Exhibit 10.41

                           MASTER SERVICES AGREEMENT

     This Master Agreement ("AGREEMENT") made this 9th day of July 2001 by and
between Introgen Therapeutics, Inc., with its principal executive offices
located at 301 at Congress Avenue, Suite 1850, Austin, Texas 78701, USA
("SPONSOR"), and PPD Development, LLC, a Texas limited liability company with
its principal executive offices located at 3151 17th Street Extension,
Wilmington, North Carolina 28412, USA along with its affiliate PPD Global Ltd
(collectively "PPD").

     WHEREAS, Sponsor is engaged in the development, manufacture, distribution,
and sale of pharmaceutical product; and

     WHEREAS, PPD is a contract research organization engaged in the business
of managing clinical research programs; and

     WHEREAS, Sponsor may wish to retain the services of PPD from time to time
to perform clinical research services in connection with certain clinical
research programs Sponsor is conducting (individually, "STUDY") as more fully
set forth in various project specific addenda to be attached to this Agreement
and incorporated herein by reference ("PROJECT ADDENDA"), which Study Sponsor
intends to submit to the United States Food and Drug Administration ("FDA") and
other international regulatory authorities as part of a marketing approval
application; and

     WHEREAS, PPD is willing to provide such services to Sponsor in accordance
with the terms and conditions of this Agreement and attached Project Addenda.

     NOW, THEREFORE, for good valuable consideration contained herein, the
exchange, receipt and sufficiency of which are acknowledged, the parties agree
as follows:

1.   PROJECT ADDENDA.
     ----------------

     1.1  In the event that the parties hereto shall reach agreement with
respect to a particular project (a "PROJECT") in connection with a Study, a
Project Addendum for said Project shall be attached and incorporated into this
Agreement, and the two shall collectively, independent from other Project
Addenda, constitute the entire agreement for the specific Project. At a minimum,
the Project Addenda for each Project shall include schedules that describe each
of the following:

     (a) - Scope of services and deliverables to be provided by PPD
           ("SERVICES");
     (b) - Milestones for the Services ("MILESTONES");
     (c) - Budget for the PPD's provision of Services ("PROJECT BUDGET"); and
     (d) - Payment schedule for the Services ("PAYMENT SCHEDULE").

     1.2  No Project Addendum shall be attached to this Agreement without first
being executed by the parties hereto. To the extent any terms set forth in a
Project Addendum shall conflict with the terms set forth in this Agreement, the
terms of this Agreement shall control, unless the

--------------------------------------------------------------------------------
                                                                          Page 1

<PAGE>
                                                       Master Services Agreement
--------------------------------------------------------------------------------

conflicting terms in this Agreement are specifically referenced in the Project
Addendum and stated to be superceded.

2.   SERVICES.
     ---------

     2.1  PPD hereby agrees to provide to Sponsor the Services described in
each Project Addendum attached to this Agreement. In performing the Services,
PPD shall comply with the terms of this Agreement, the applicable Project
Addendum (including the Protocol described), the written instructions of
Sponsor, standard operating procedures approved by Sponsor, relevant
professional standards and all applicable laws, rules and regulations,
including, but not limited to, the Federal Food, Drug and Cosmetic Act and the
regulations and guidelines promulgated pursuant thereto for the conduct of
Clinical Trials used to support marketing approval for pharmaceutical products.

     2.2  In the event that PPD is requested or required to perform services
and/or deliverables for a Project beyond those that are specifically set forth
in the pertinent Project Addendum's description of Services, any such
additional services and/or deliverables, and the milestones, project budget and
payment schedule therefor, must be mutually agreed upon by the parties in
writing prior to the provision of said services and deliverables. Said mutually
agreed upon writing shall be an amendment to the pertinent Project Addendum.
The services and deliverables, and the corresponding milestones, project budget
and payment schedule set forth in that amendment shall be deemed to be included
within the Services, Milestones, Project Budget and Payment Schedule for the
pertinent Project Addendum.

3    COMPENSATION AND PAYMENT.
     -------------------------

     3.1  The Project Budget set forth in each Project Addendum shall be fully
transparent and include all planned activities and all planned costs for the
applicable Project. For each Project, Sponsor need not pay for any costs-nor
reimburse PPD for any out-of-pocket expenses-other than those set forth in the
applicable Project Budget, unless the parties otherwise agree in writing.

     3.2  Except as otherwise provided in an applicable Payment Schedule, PPD
shall, on a monthly basis, submit to Sponsor invoices for each Project Addendum
describing the Milestones successfully performed by PPD during the preceding
month. Sponsor shall pay said invoices within thirty (30) days of receipt,
subject to Section 3.4.

     3.3  Travel and other out-of-pocket expenses that PPD reasonably incurs in
connection with its performance of Services and that are provided for in an
applicable Project Budget shall be reimbursed by Sponsor within thirty (30)
days of Sponsor's receipt of PPD's invoice, subject to Section 3.4 and the
following:

          (a)  PPD's invoice shall include an itemized statement listing all
such expenses, together with any appropriate supporting documentation therefor.

--------------------------------------------------------------------------------
                                                                          Page 2
<PAGE>
                                                       Master Services Agreement
--------------------------------------------------------------------------------

           (b)  In situations where expenses incurred by PPD may also be
allocated to PPD's other customers (e.g., a site visit to an institution
participating in a Study and a clinical study sponsored by one or more of PPD's
other customers), PPD shall invoice Sponsor for only its equitable portion of
such expenses. Whenever possible, PPD shall manage its activities on behalf of
Sponsor and its other customers in such a fashion  as to maximize the
opportunity for the sharing of expenses.

           (c)  In order to receive reimbursement for any out-of-pocket
expenses, PPD must provide a copy of a written receipt of any expense of [*] or
more. Specific prior approval shall be obtained for any expense of [*] or more.
PPD will not be asked to initiate work before such approval is given. PPD will
conform to PPD's Travel Policy.

           (d)  It is expressly understood that all out-of-pocket expenses shall
not have profit, overhead or general administration factors applied to them and
shall be separately accounted for by PPD. Any savings due to under-spending in
Investigator grants or laboratory charges may not be applied to labor or other
out-of-pocket costs without the prior written approval of Sponsor. As used in
this Agreement, "INVESTIGATOR" means a licensed health-care professional who PPD
or Sponsor engages to conduct a Study. PPD will not make investigator payments
on behalf of the Sponsor until such payment is first received from the Sponsor.

     3.4  Sponsor need not pay for any portion of an invoice that contains
disputed amounts. Any disagreement between Sponsor and PPD regarding Services
performed or expenses incurred by PPD and specified on an invoice must be
resolved in full before that portion of the invoice shall be paid by Sponsor.
Sponsor need not pay for any time or expense incurred by PPD in reconciling
invoices. In the event of a dispute regarding an invoice, Sponsor shall pay the
undisputed portion and the parties shall negotiate in good faith in an effort
to resolve promptly such dispute. In no event shall Sponsor be obligated to pay
any invoices which are received more than one hundred and twenty (120) days
after completion or termination of the Project. Sponsor should contact PPD ten
(10) days after receiving an invoice with any disputes to allow resolution and
prompt payment.

     3.5  Payments to PPD shall be made to:

          PPD Development, LLC
          P.O. Box 75468
          Charlotte, NC 28275-5468
          Tax ID# 74-2325267

     3.6  Taxes (and any penalties thereon) imposed on any payment made by
Sponsor to PPD shall be the responsibility of PPD.

     3.7  Sponsor, or its auditors, may audit any financial records of PPD
associated with this Agreement upon 48 hours notice until two years after the
expiration or termination of this Agreement. Such records may include, invoices
from third parties, contracts with third parties and payments relating to the
project or Study. To the extent such records are not separable from other
customer records, PPD shall grant reasonable access to the record to an
independent auditor

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                          Page 3
<PAGE>
                                                       Master Services Agreement
--------------------------------------------------------------------------------

selected by Sponsor. In no event shall such auditors be entitled to disclose to
Sponsor any information relating to projects for PPD's other customers. In the
event it is determined that PPD has overcharged Sponsor for any out-of-pocket
expenses, PPD shall promptly reimburse Sponsor for the amount of such overcharge
and, if such overcharge represents more than five percent (5%) of the
out-of-pocket expenses for a particular Project, pay Sponsor's reasonable fees
and expenses incurred in connection with such audit.

4.   PROJECT MANAGEMENT.
     ------------------

     4.1  PERFORMANCE METRICS. PPD understands that the Studies described in the
Project Addenda are pivotal studies for Sponsor and will be filed by Sponsor as
part of a marketing application to worldwide regulatory authorities, including
the U.S. FDA, and, therefore, Sponsor has established particular timeframes for
filing marketing applications to various regulatory authorities. PPD shall
exercise all reasonable efforts to meet said established timelines. Accordingly,
for any particular Study, in the event PPD's services do not conform to its
obligations set forth in the Study contract, PPD shall be obligated to reperform
the non-conforming services at no cost to Sponsor. In the event reperformance
does not cure the non-conforming services within 30 days of written notice of
the non-conformance, PPD shall not be entitled to compensation for the non-
conforming services.

     4.2  MUTUALLY ACCEPTABLE SOLUTION. In the event a particular Project or
Study falls behind schedule, PPD shall propose, and the parties shall endeavor
to agree upon, a mutually acceptable solution to bring the Project or Study back
onto schedule or to take whatever other action is required to remedy the
problem. Sponsor will not be responsible for reimbursing PPD for any costs or
expenses incurred in accordance with this Article 4 unless such delay is a
product of Force Majeure or Sponsor delay. For the avoidance of doubt, nothing
in this Article 4 is intended to limit or prevent Sponsor from exercising its
rights under Section 4.1 (Performance Metrics) or Article 6 (Term and
Termination of Agreement) hereof.

5.   TRANSFER OF OBLIGATIONS.
     -----------------------

     This Agreement contemplates that Sponsor will transfer various regulator
responsibilities to PPD, as defined by a Project Addendum. PPD agrees to accept
the transferred responsibilities and agrees to carry out diligently all
transferred obligations. Pursuant to 21 CFR section 312.52, or other applicable
regulatory law, rules or regulation, Sponsor and PPD shall cooperate in the
completion of a Transfer of Obligations Form in conjunction with each Project
Addendum. Any responsibilities not specifically transferred by Sponsor in the
Transfer of Obligations Form or similar document with the FDA, where
appropriate, or as required by law or regulation, shall remain the
responsibility of Sponsor.

6.   TERM AND TERMINATION.
     --------------------

     6.1  The term of this Agreement shall commence as of the date hereof and,
unless earlier terminated in accordance with this Section 6, continue for [*]
years from the commencement date; Project Addenda executed under this Agreement
prior to this Agreement's termination shall continue

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                          Page 4
<PAGE>
                                                       Master Services Agreement
--------------------------------------------------------------------------------

uninterrupted under the terms and conditions of this Agreement unless the
Project Addenda are otherwise terminated as provided herein."

     6.2  This Agreement and any Project Addendum may be terminated with or
without cause by Sponsor upon thirty (30) days prior written notice. Sponsor
may also, without terminating this Agreement or the applicable Project
Addendum, elect to assume responsibility for managing and monitoring all or any
portion of a Project or Study (in which case, the Project Budget for the
Services, and the Payment Schedule for the various Milestones shall be reduced
accordingly).

     6.3  If either party materially defaults under this Agreement ("DEFAULTING
PARTY"), the other ("NON-DEFAULTING PARTY") may give the Defaulting Party
written notice of the default and elect to terminate this Agreement upon
written notice to the Defaulting Party if, within thirty (30) days after
delivery of the default notice by the Non-Defaulting Party, the Defaulting
Party fails to resolve the default by (i) curing the default or beginning the
cure of the default and diligently completing the cure of the default by the
end of the aforementioned thirty (30) day time period, (ii) providing a written
explanation reasonably satisfactory to the Non-Defaulting Party that a default
has not occurred, or (iii) entering into a written agreement with the
Non-Defaulting Party for the cure or other resolution of the default. The
rights granted to the Non-Defaulting Party pursuant to this Section 6.3 shall
be in addition to and not in substitution for any other remedies that may be
available to such party. Except as otherwise expressly stated herein,
termination shall not relieve the Defaulting Party from liability and damages
to the other party for breach of this Agreement.

     6.4  This Agreement may be terminated by a party upon written notice to
the other in the event that (i) the other party shall make an assignment for
the benefit of its creditors, file a petition in bankruptcy, petition or apply
to any tribunal for the appointment of a custodian, receiver or any trustee for
it or a substantial part of its assets, or shall commence any proceeding under
any bankruptcy, reorganization, arrangement, readjustment of debt, dissolution
or liquidation law or statute of any jurisdiction, whether now or hereafter in
effect; or (ii) if there shall have been filed against the other party any such
bona fide petition or application, or any such proceeding shall have been
commenced against it, in which an order for relief is entered or which remains
undismissed for a period of ninety (90) days or more; or (iii) if the other
party by any act or omission shall indicate its consent to, approval of, or
acquiescence in any such petition, application, or proceeding or order for
relief or the appointment of a custodian, receiver or trustee for it or any
substantial part of its assets, or shall suffer any such custodianship,
receivership or trusteeship to continue undischarged for a period of ninety
(90) days or more. Termination shall be effective upon the date specified in
such notice.

     6.5  Subject to the second sentence of Section 6.2, the termination of
this Agreement by either party shall automatically terminate any and all
Project Addenda, unless otherwise agreed.

     6.6  Upon termination of this Agreement or a Project Addendum pursuant to
this Section 6, PPD shall cooperate with Sponsor to provide for an orderly
wind-down and transfer of the data and work product provided by PPD hereunder.

-------------------------------------------------------------------------------
                                                                         Page 5

<PAGE>
                                                       Master Services Agreement
--------------------------------------------------------------------------------

     6.7  The obligations of the parties contained in Articles 3, 6 and 7
through 25 hereof shall survive termination of this Agreement.

7.   PERSONNEL.
     ----------

     7.1  The Services with respect to each Project shall be performed by PPD
under the direction of the person identified as the "PROJECT MANAGER" in the
applicable Project Addendum or such other person acceptable to Sponsor as PPD
may from time to time designate the Project Manager, such Sponsor acceptance to
be in writing and not to be unreasonable withheld.

     7.2  PPD shall perform the Services with respect to each Project with
highly qualified, trained and educated personnel knowledgeable in U.S. and
international Good Clinical Practices (GCPs), applicable regulatory
requirements, clinical project management, pharmaceutical drug development and,
if possible, in Sponsor therapeutic areas and products. PPD is responsible for
the training of its staff in order to maintain their knowledge to the state of
the art. The costs for such training will be fully covered by PPD.

     7.3  Any "KEY PERSONNEL" described in a Project Addendum shall not - be
removed from the relevant Project, nor shall the responsibilities of such Key
Personnel be materially reduced or altered except where said Key Personnel has
terminated employment with PPD, has been promoted, is out on medical leave, is
otherwise physically unable to perform the required services or without the
prior written consent of Sponsor, which consent shall not be unreasonably
withheld.

     7.4  PPD shall terminate immediately the assignment of any PPD staff
member working under this Agreement for reasonable cause identified by Sponsor.

     7.5  PPD shall not subcontract or assign any Services under a Project
Addendum without the prior written consent of Sponsor.

     7.6  During the period in which a particular Project is being conducted,
neither party shall recruit, hire or employ any personnel of the other who is
material to the performance of the particular Project without the prior written
consent of the other party.

8.   CONFIDENTIALITY.
     ----------------

     8.1  PPD agrees to treat any confidential or proprietary information
obtained from Sponsor or generated or created by PPD as a direct and sole
result of performing the Services under this Agreement (other than, unless
specifically included in a Project Addendum, any PPD Property as defined in
Section 9.3)(to be referred to herein as the "CONFIDENTIAL INFORMATION"), as
the confidential and exclusive property of Sponsor.

     8.2  PPD agrees that it will use the Confidential Information only to
provide the Services and for no other purpose without the prior written consent
of Sponsor. PPD agrees not to disclose any of the Confidential Information to
any third party without first obtaining the written consent of Sponsor. PPD
further agrees not to disclose the Confidential Information to any of its
directors,

--------------------------------------------------------------------------------
                                                                          Page 6

<PAGE>
                                                       Master Services Agreement
--------------------------------------------------------------------------------

officers, employees, agents, representatives and advisors other than those who
have a need to know such information in order to perform Services and who are
bound in writing by obligations of confidentially and non-use with respect to
the Confidential Information at least as stringent as those provided in this
Agreement.

     8.3  The above provisions of confidentiality shall not apply to that part
of the Confidential Information which PPD is able to demonstrate by documentary
evidence:

          (a) was in PPD's possession prior to receipt from Sponsor, as
established by contemporaneous written records, or is developed independent
from a Project; or

          (b) was in the public domain at the time of receipt from Sponsor; or

          (c) becomes part of the public domain without breach of
confidentiality by PPD, its directors, officers, employees, agents,
representatives or advisors; or

          (d) is lawfully received by PPD from some third party having a right
of further disclosure.

     8.4  In the event that PPD is required by law to disclose any Confidential
Information, PPD will, as soon as possible (and in any event prior to such
disclosure), notify Sponsor of such requirement so that Sponsor may seek a
protective order or other appropriate remedy, or in its sole discretion, waive
compliance with this Section 8.4. In the event that no such protective order or
other remedy is obtained, or in the event that Sponsor waives compliance with
this Section 8.4, PPD will furnish only that portion of the Confidential
Information which it is advised by counsel it is legally required to furnish
and will exercise all reasonable efforts to obtain reasonable assurance that
confidential treatment will be accorded the Confidential Information so
furnished.

     8.5  PPD agrees that upon termination or expiration of this Agreement or,
at Sponsor's request, it shall (and shall cause its directors, officers,
employees, agents, representatives and advisors to) return to Sponsor all parts
of the Confidential Information provided by Sponsor in documentary form and
return or destroy any copies thereof made by PPD, its directors, officers,
employees, agents or representatives. Notwithstanding the foregoing, PPD may
retain copies of any such Confidential Information as is reasonably necessary
for regulatory, insurance or business purposes, subject to the ongoing
obligation to maintain the confidentiality of such information.

     8.6  PPD acknowledges that disclosure or distribution of the Confidential
Information or use of the Confidential Information contrary to the terms of this
Agreement may cause irreparable harm for which damages at law may not be an
adequate remedy, and agrees that the provisions of this Agreement prohibiting
disclosure or distribution of the Confidential Information or use contrary to
the provisions hereof may be specifically enforced by a court of competent
jurisdiction in addition to any and all other remedies available at law or in
equity.

--------------------------------------------------------------------------------
                                                                          Page 7
<PAGE>

                                                       Master Services Agreement
--------------------------------------------------------------------------------

     8.7  All Confidential Information containing personal data shall be handled
in accordance with all applicable law, including, but not limited to the
European Data Protection Directive [EC/95/46], Health Insurance Portability and
Accountability Act and applicable implementing regulations.

9.   OWNERSHIP.
     ----------

     9.1  Neither anything contained herein nor the delivery of any information
to a party shall be deemed to grant the receiving party any right or licenses
under any patents or patent applications or to any know-how, technology or
inventions of the disclosing party.

     9.2  Sponsor Property.

          (a) Inventions. Subject to Section 9.3 below, PPD shall disclose to
Sponsor, hereby assigns to Sponsor, and shall continue to assign to Sponsor
immediately upon creation during the term of this Agreement, all rights PPD or
its directors, officers, employees, agents or representatives may have in any
invention, technology, know-how or other intellectual property that is: (1)
conceived of, made and/or reduced to practice in the course of performing work
under this Agreement; or (2) specifically set forth as a deliverable under a
Project Addendum (collectively, "INVENTIONS"). In addition, PPD agrees to
assist Sponsor, at Sponsor's expense, in obtaining or extending protection
therefor. Without limiting the foregoing, whenever requested to do so by
Sponsor, PPD shall execute any and all applications, assignments, or other
instruments, and give testimony which Sponsor shall deem necessary to apply for
and maintain letters of patent of the United States or any other country or to
protect otherwise Sponsor's interest in the Inventions.

          (b) Information. Subject to section 9.3 below, as between PPD and
Sponsor, all budgets, bids, proposals, Protocols, coding dictionaries and other
materials, documents, information, and programs of every kind and description
supplied to PPD or Investigators by or on behalf of Sponsor, and, all
materials, documents and information prepared or developed by PPD or
Investigators in the course of performing the work provided for in this
Agreement, shall be the sole and exclusive property of Sponsor, and upon
request, PPD will provide Sponsor with all or any designated portion of such
property, or copies thereof.

     9.3  PPD Property. It is acknowledged that PPD possesses certain
inventions, processes, know-how, trade secrets, improvements, other
intellectual properties and other assets, including but not limited to, data
processes, technology, means or know-how developed by PPD which relate to data
collection or data management and laboratory analyses, analytical methods,
procedures and techniques, computer technical expertise and software (including
codes) which have been independently developed without the benefit of any
information provided by Sponsor (collective, "PPD Property"). Sponsor and PPD
agree that any PPD Property or improvements thereto are the sole and exclusive
property of PPD.

--------------------------------------------------------------------------------
                                                                          Page 8
<PAGE>
                                                       Master Services Agreement
--------------------------------------------------------------------------------

     9.4  In furtherance of the limitations set forth in this Article 9, it is
expressly understood that PPD will not use any materials provided by or on
behalf of Sponsor in connection with the Project or Study for any purposes
other than for fulfilling its obligations hereunder.

10.  PUBLICATION.
     ------------

          PPD may not publish any articles or make any presentations relating
to the Services or referring to data, information or materials generated as
part of the Services, in whole or in part, without the prior written consent of
Sponsor.

11.  INDEMNIFICATION.
     ----------------

     11.1  Sponsor shall indemnify PPD, it directors, officers, employees, and
affiliates ("PPD INDEMNITEES") for any and all damages, costs, expenses and
other liabilities, including reasonable attorney's fees and court costs,
incurred by PPD as a result of any claim, suit action, demand or judgment for
personal injury (i) suffered by a patient participating in the Study as a
result of the administration of the Study Drug in accordance with the Protocol
provided to PPD by Sponsor, from protocol required procedures; or (ii) arising
from or growing out of the negligence of Sponsor or the breach by it of this
Agreement, or resulting from PPD following the written directive of Sponsor,
provided in each case that such injury was not the result of the failure to
administer the Study Drug in accordance with the Protocol or the negligence or
willful misconduct of any PPD Indemnitee or their respective employees or
agents. For the purpose of this Agreement, "STUDY DRUG" means any drug (in
monotherapy or in combination) to be used in a Study, as described in the
Protocol.

     11.2  PPD shall indemnify Sponsor, its directors, officers, and employees
("SPONSOR INDEMNITIES") for any and all damages, costs, expenses and other
liabilities, including reasonable attorney's fees and court costs, incurred by
Sponsor as a result of any claim, suit, action, demand or judgment arising from
or growing out of (i) the negligence or willful misconduct of PPD or its
employees or agents or the breach of any provision of this Agreement, or (ii)
the claimed or alleged status of any employee or agent of PPD as an employee or
agent of Sponsor, provided in each case that such claim, suit, action, demand
or judgment was not the result of the negligence or willful misconduct of any
Sponsor Indemnitee or their respective employees or agents.

     11.3  Any party liable to provide the indemnification hereunder shall be
entitled, at its option, to control the defense and settlement of any claim on
which it is liable, provided that the indemnifying party shall act reasonably
and in good faith with respect to all matters relating to the settlement or
disposition of the claim as the disposition or settlement relates to the party
being indemnified. The indemnified party shall reasonably cooperate in the
investigation, defense and settlement of any claim for which indemnification is
sought hereunder and shall provide prompt notice of any such claim or reasonably
expected claim to the indemnifying party. An Indemnified party shall have the
right to retain its own separate legal counsel at its own expense.

--------------------------------------------------------------------------------
                                                                          Page 9
<PAGE>
                                                       Master Services Agreement
--------------------------------------------------------------------------------

12.  INSURANCE.
     ----------

     Each party will procure and maintain throughout the term of this Agreement
Comprehensive or Commercial Form General Liability Insurance, and PPD will
additionally procure and maintain throughout the term of this Agreement
Professional Liability Insurance (contract liability included), or in each case
an equivalent program of self insurance with limits not less than:

          (a) Combined Single Limit Per Occurrence - [*]
          (b) General and Professional Annual Aggregate - [*]

     Each party agrees to furnish the other, upon request, an original
certificate of insurance reasonably acceptable to the other indicating the
required coverage. Each party agrees that the insurance will not be canceled
while this Agreement is in effect without thirty (30) days prior written notice
to the other party. Should PPD at any time neglect or refuse to provide the
insurance required herein, or should such insurance be canceled, Sponsor shall
have the right to procure the same and the cost thereof shall be deducted from
any compensation then due or thereafter to become due to PPD. PPD shall not
commence work under this Agreement until the insurance required herein has been
obtained.

13.  REPRESENTATION AND WARRANTIES
     -----------------------------

     13.1  PPD represents and warrants to Sponsor that:

           (a) it is authorized to enter into this Agreement, and that its
execution, delivery and performance of this Agreement will not conflict with or
constitute a default under any other agreement to which it is a party or by
which its assets are bound; and

           (b) all aspects of PPD's facilities which may be used in the
performance of any Services, including without limitation the databases to be
used by PPD for the tracking, handling, recording, reporting and transmitting
of data generated during the Projects and Studies have been fully verified and
validated according to applicable industry standards.

           (c) It is not a party to any agreement that would prevent it from
fulfilling its obligations under this Agreement and that, during the term of
this Agreement, it will not enter into any agreement to provide services that
would in any way prevent it from providing the Services contemplated under this
Agreement.

     13.2  Sponsor represents and warrants to PPD that it is authorized to
enter into this Agreement, and that its execution, delivery and performance of
this Agreement will not conflict with or constitute a default under any other
agreement to which it is a party or by which its assets are bound.

14.  INDEPENDENT CONTRACTOR RELATIONSHIP.
     ------------------------------------

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 10
<PAGE>
                                                       Master Services Agreement
--------------------------------------------------------------------------------

     The parties hereto are independent contractors and nothing contained in
this Agreement shall be construed to place them in the relationship of partners,
principal and agent, employer/employee or joint venturer. Both parties agree
that neither party (including such party's employees, servants, agents or
independent contractors) shall have power or right to bind or obligate the other
party, nor shall either hold itself out as having such authority.

15.  PUBLICITY.
     ----------

     Except as required by law, neither party shall use the name of the other
party nor of any employee of the other party in connection with any publicity
without the prior written approval of the other party.

16.  FORCE MAJEURE.
     --------------

     Both parties to this Agreement shall be excused from the performance of
their obligations under this Agreement if such performance is prevented by force
majeure and the non-performing party promptly provides notice of the prevention
to the other party. Such excuse shall be continued so long as the condition
constituting force majeure continues and the non-performing party takes
reasonable efforts to remove the condition. Any timelines affected by such force
majeure shall be extended for a period equal to that of the delay and any
affected Study Budgets shall be adjusted to reflect costs increases resulting
from force majeure. For purposes of this Agreement, force majeure shall include
conditions which are beyond the reasonable control of a party and which could
not have been avoided by the exercise of reasonable diligence, including without
limitation, an act of God, compliance with any regulation, law or order of any
government, war, civil commotion, epidemic, or failure or default of public
utilities.

17.  ACCESS TO SITES AND DATA.
     -------------------------

     17.1 PPD shall ensure that Sponsor's authorized representatives upon
reasonable notice, and regulatory authorities to the extent permitted by law,
may, during regular business hours, (i) examine and inspect the facilities of
PPD or any Investigator site used in the Project and/or Study, and (ii) inspect
and copy all data, documentation and work products relating to the Project
and/or Study, including, without limitation, the medical records of any patient
participating in the Project and/or Study. Sponsor's right to inspect and copy
all data, documentation, and work products relating to the Project and Study
shall survive any termination of this Agreement or the completion of the Project
and Study for two years after PPD stops providing services hereunder, or such
longer period as shall be required by law.

     17.2 Notwithstanding anything else in this Agreement to the contrary, PPD
shall retain and preserve one (1) copy only of all records relating to the
Project and Study for two (2) years after PPD stops providing services
hereunder or such period as shall be required by law (such period being
referred to herein as the "Retention Period"). At the end of such period, PPD
may destroy all such material upon giving Sponsor written notice of its intent
to do so at least sixty (60) days prior to destruction.

--------------------------------------------------------------------------------
                                                                         Page 11
<PAGE>
                                                       Master Services Agreement
--------------------------------------------------------------------------------

18. REGULATORY COMPLIANCE AND INSPECTIONS.
    --------------------------------------

    Each party acknowledges that the other party may respond independently
to any regulatory correspondence or inquiry in which such party or its
affiliates is named. Each party, however, shall:

         (a) notify the other party promptly of any FDA or other governmental or
regulatory inspection or inquiry concerning any Study or Project of Sponsor in
which PPD is providing Services, including, but not limited to, inspection of
investigational sites or laboratories;

         (b) forward to the other party copies of any correspondence from any
regulatory or governmental agency relating to such a Study or Project,
including, but not limited to, Form FD-483 notices, or warning letters, even if
they do not specifically mention the other party; and

         (c) obtain the written consent of the other party, which will not
unreasonably be withheld, before referring to the other party or any of its
affiliates in any regulatory correspondence. Where reasonably practicable, each
party will be given the opportunity to have a representative present during an
FDA or regulatory inspection. Each party, however, acknowledges that it may not
direct the manner in which the other party fulfills its obligations to permit
inspection by governmental entities.

    Each party agrees that, during an inspection by the FDA or other regulatory
authority concerning any Study or Project of Sponsor in which PPD is providing
Services, it will not disclose information and materials that are not required
to be disclosed to such agency without the prior consent of the other party,
which consent shall not unreasonably be withheld. Such information and materials
include, but are not limited to, the following:

         (a) financial data and pricing data (including, but not limited to, the
budget and payment schedule); and

         (b) personal data (other than data relating to the qualification of
technical and professional persons performing functions subject to the
regulatory requirements).

19. DEBARMENT.
    ----------

    19.1 PPD hereby certifies that it has not been debarred, and has not been
convicted of a crime which could lead to debarment, under any applicable law,
rule or regulation, as amended. In the event that PPD or any of its officers,
directors, employees or agents under contract to perform services under a
Project Addendum with Sponsor becomes debarred or receives notice of action or
threat of action with respect to its debarment, PPD shall notify Sponsor
immediately, and Sponsor shall have the right to immediately terminate this
Agreement pursuant to Article 4.

     19.2 PPD hereby certifies that it has not utilized, and will use its
reasonable best efforts not to utilize, the services of any individual or entity
in the performance of services under this  Agreement or any Project Addendum
that has been debarred or that has been convicted of a crime that could lead to
debarment under any applicable law, rule or regulation, as amended. In the
event that PPD receives notice of the debarment or threatened debarment of any
such individual or entity,

--------------------------------------------------------------------------------
                                                                         Page 12
<PAGE>
                                                       Master Services Agreement
--------------------------------------------------------------------------------

PPD shall notify Sponsor immediately, and Sponsor shall have the right to
immediately terminate this Agreement pursuant to Article 4.

20.  NOTICES.
     --------

     Any notice required or permitted to be given hereunder by either party
hereunder shall be in writing and shall be deemed given on the date received if
delivered personally or five (5) days after the date postmarked if sent by
registered or certified mail, return receipt requested, postage prepaid to the
following address (or such other address or addresses of which a party shall
have given written notice to the other):

     If to PPD:          PPD Development, LLC
                         3151 17th Street Extension
                         Wilmington, North Carolina 28412
                         Attention: CEO
                         Tel: (910) 251-0081
                         Fax: (910) 762-5820

     If to Sponsor:      Introgen Therapeutics, Inc.
                         301 at Congress Avenue
                         Suite 1850
                         Austin, Texas 78701
                         Attention: President
                         Tel: (713) 797-9960
                         Fax: (713) 797-9913

21.  GOVERNING LAW.
     --------------

     This Agreement and the rights and obligations of the parties hereunder
shall be governed by the laws of the State of Texas, without regard to
conflict-of-law principles.

22.  SEVERANCE.
     ----------

     If any one or more provisions of this Agreement shall be found to be
illegal or unenforceable in any respect from which no appeal can be taken, the
validity, legality and enforceability of the remaining provisions shall not in
any way be affected or impaired thereby. In such case, the parties shall in
good faith modify or substitute such provision consistent with the parties'
original intent.

23.  WAIVER.
     -------

     Waiver or forbearance by either party or the failure by either party to
claim a breach of any provision of this Agreement or exercise any right or
remedy provided by this Agreement or applicable law, shall not be deemed to
constitute a waiver with respect to any subsequent breach of any provision
hereof.

--------------------------------------------------------------------------------
                                                                         Page 13
<PAGE>
                                                       Master Services Agreement
--------------------------------------------------------------------------------

24.  CHANGES AND MODIFICATION.
     -------------------------

     No changes or modifications of this Agreement or any Project Addendum
shall be deemed effective unless in writing and executed by the parties hereto.

25.  ASSIGNMENT.
     -----------

     This Agreement and any Project Addenda may not be assigned by PPD without
the prior written consent of the Sponsor.

26.  ENTIRE AGREEMENT.
     -----------------

     This Agreement (including the Project Addenda) represents the complete and
entire understanding between the parties regarding the subject matter hereof
and supersedes all prior negotiations, representations or agreements, either
written or oral, regarding this subject matter.

27.  COUNTERPARTS.
     -------------

     This Agreement may be executed in counterparts, each of which shall be
deemed an original and all of which shall constitute one and the same agreement.

     IN WITNESS THEREOF, this Agreement has been executed by the parties hereto
through their duly authorized officers as of the date set forth above.

PPD DEVELOPMENT, LLC                         INTROGEN THERAPEUTICS, INC.

By: /s/ Paul S. Covington, M.D.             By: /s/ J. David Enloe, Jr.
   --------------------------------             ------------------------------

Name: Paul S. Covington, M.D.                Name: J. David Enloe, Jr.
     ------------------------------               ----------------------------

Title: Sr. V.P. Medical Affairs/CSO          Title: V.P. Operations
      -----------------------------                ---------------------------

Approved
MC 12/17/01
PPD CONTACTS

--------------------------------------------------------------------------------
                                                                         Page 14

<PAGE>
                                                                      [*]

                                PROJECT ADDENDUM

     This agreement ("PROJECT AGREEMENT") made this 1st day of September 2001 by
and between Introgen Therapeutics, Inc., with its principal executive offices
located at 301 at Congress Avenue, Suite 1850, Austin, Texas 78701, USA
("SPONSOR"), and PPD Development, LLC, a Texas limited liability company with
its principal executive offices located at 3151 17th Street Extension,
Wilmington, North Carolina 28412, USA along with its affiliate PPD Global Ltd
(collectively "PPD").

     WHEREAS, a Master Services Agreement ("Agreement") by and between PPD and
Sponsor was executed July 20, 2001; and

     WHEREAS, pursuant to Section 1 of the Agreement the parties now enter into
this Project Addendum for the purposes of setting forth the responsibilities and
obligations of the parties in regards to conducting certain clinical research
programs entitled "A Phase III, Multicenter, open-label, randomized study to
compare the overall survival and safety of bi-weekly intratumoral administration
of RPR/INGN 201 vs. weekly methotrexate in patients with refractory squamous
cell carcinoma of the head and neck" and "A Phase III, Multicenter, open-label,
randomized study to compare the effectiveness and safety of intratumoral
administration of RPR/INGN 201 in combination with chemotherapy vs. chemotherapy
alone in patients with recurrent squamous cell carcinoma of the head and neck"
("Study") under Sponsor's protocols #T301 and T302 ("Protocol") which are
incorporated herein by reference.

     NOW, THEREFORE, for good and valuable consideration contained herein, the
exchange, receipt and sufficiency of which are acknowledged, the parties agree
as follows:

1. SERVICES.
   ---------

     PPD shall perform services as required in the Protocol and in the Services
section of this Project Addendum attached as Exhibit A.1 through A.5.

----------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                          Page 1

<PAGE>
                                                               Project Addendum
-------------------------------------------------------------------------------

2. COMPENSATION AND PAYMENT.
   -------------------------

     2.1 - Compensation - For its performance under this Project Addendum, PPD
shall be compensated in the manner and in the amounts set forth on Exhibit B
attached hereto. Costs labeled "fixed" on Exhibit B are fixed costs per unit,
and PPD will be compensated for such costs in the amount of the Cost Per Unit
times the total number units of such item (as described on Exhibit B) actually
used or consumed. Costs labeled "variable" on Exhibit "B" are monthly charges
and will be in the same amount each month throughout the term of the agreement.
Costs labeled "direct" costs on Exhibit "B" represent compensation to PPD for
services of all of its personnel involved in the study and includes all
overhead and other costs and expenses of PPD in connection with the study, such
as, for example, long distance telephone charges photocopying, shipping and
courier charges, and all other expenses whatsoever, except for those
categorized as "pass-through costs" on Exhibit "B", and except that in
connection with services provided outside the United States of America, PPD
will also pass through its out-of-pocket expenses paid to third parties for
such items as long distance telephone, shipping, outside copying, courier
charges, etc.

The costs categorized as "pass-through costs" on Exhibit "B" represent PPD's
estimates of out-of-pocket expenses related to each of the activities set forth
thereon. For items such as travel, transportation, hotel, meals, and other
similar expenses, PPD will be reimbursed for [*] in accordance with PPD's travel
policy attached hereto as Exhibit "D", and in accordance with section 3.3 of the
Agreement. Thus, it is estimated that PPD's aggregate compensation based on the
estimates of fixed and variable costs set forth on Exhibit B, will approximate
[*], of which [*] will be direct costs, and of which [*] will constitute
pass-through costs. Such estimated compensation for direct costs is subject to
performance-based adjustment as provided in Section 2.2 below.

The parties understand and agree that the enrollment rates and the number of
sites to be contracted with herein are good-faith estimates only and PPD shall
exercise all reasonable diligence to meet enrollment and site sign-up
expectations.

Should a change in any of the key study parameters, e.g., number of sites,
number of patients, number of CRF pages, number of statistical tables or
listings, study timeline or protocol design result in an increase or decrease in
the study budget, such financial implications will be summarized in writing and
subject to prior written approval by Sponsor. The parties agree to mutually
review all such estimates at least quarterly during the term of this Agreement,
and to revise the budget set forth on Exhibit "B" in the event of material
changes in such estimates, PPD acknowledges that Introgen is conducting studies
of the identical drugs in other countries using clinical research organizations
other than PPD. The estimates of a number of sites, number of patients, number
of CRF pages, etc. estimated herein is based, in part, upon Introgen's
estimates of such activities in other countries. Should Introgen enroll sites
and/or patients more quickly or in larger numbers in such other countries, the
number of sites and patients needed which are the subject of this Project
Addendum will decrease, which may result in a reduction of direct and
pass-through costs payable to PPD hereunder.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

-------------------------------------------------------------------------------
                                                                         Page 2

<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

The indirect reimbursable costs are estimated and may vary as circumstances
require.

2.2  Performance-based Adjustments

     (a)  The compensation otherwise payable to PPD hereunder (referred to as
     "direct costs" on Exhibit "B"), is subject to adjustment of up to [*]
     upwards based upon PPD's performance in meeting [*] pre-determined
     milestones described on Exhibit "C" attached hereto. With respect to each
     of milestone numbers [*] through [*], PPD's direct costs will be increased
     by [*] if the milestone is met. With respect to the [*] milestone, the
     fixed direct costs will be increased by [*] if the milestone is met.

     (b)  In addition, PPD can earn further additional compensation by meeting
     [*] or more of [*] additional milestones. PPD will be paid (i) [*] of total
     direct costs, not to exceed [*], of additional compensation if at least [*]
     patients are enrolled in the T301 study on or before [*], and (ii) another
     [*] of total direct costs, not to exceed [*] of additional compensation if
     at least [*] patients are enrolled in the T302 study on or before [*], and
     (iii) another [*] of total direct costs, not to exceed [*] of additional
     compensation if at least [*] patients are enrolled in the T301 study on or
     before [*], and (iv) another [*] of total direct costs, not to exceed [*]
     of additional compensation if at least [*] patients are enrolled in the
     T302 study on or before [*]. To be counted for purposes of these payments,
     a patient must be enrolled in the study at a site in the [*] or [*]
     contracted with and monitored through the efforts of PPD under this Project
     Addendum, and must have received at least [*] treatment of the study drug.

     (c)  The above notwithstanding, all performance-based compensation
     described in Sections 2.2.(a) and (b) will be first allocated and paid
     directly to [*] working on this project in an amount up to [*], as
     determined by Introgen, in its sole discretion [*]. Upon completion of the
     project, [*] will be allocated and paid to [*], and other PPD personnel,
     all as mutually determined by Introgen and PPD, as a bonus award for
     unusual efforts and success in reaching milestones set out in this Project
     Addendum. These payments will constitute compensation to such [*] from PPD.
     This provision is solely for the benefit of the parties hereto and is not
     enforceable by any [*].

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                          Page 3

<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

     (d)  Failure to meet milestones will not, in itself, constitute default by
     PPD under this Project Addendum, but will result in failure to earn
     additional compensation described above. Such failure to earn additional
     compensation in the event of failure to meet one or more milestones will
     apply without regard to whether there is fault of PPD or Introgen or any
     other event or occurrence, including force majeure as defined in Paragraph
     16 of the Agreement, and without regard to any other defense or excuse on
     the part of PPD. The performance-based adjustments are intended to provide
     an incentive to PPD and its personnel to go beyond what is normally
     expected in attempting to reach the milestone and to provide rewards in the
     event milestones are reached. The performance-based adjustments are agreed
     to in recognition that the timely completion of the tasks will add value to
     Introgen's business, and is not intended as a penalty for non-performance
     or default.

     2.3 - Payment - Payment for the direct and pass-through costs will be made
according to the budget and payment schedules attached as Exhibit "B". There
will be no increase in direct or pass-through costs over those provided in the
budget set forth on Exhibit B unless those increases are first approved in
writing by an officer of Introgen at the level of Vice President or higher. PPD
shall invoice Introgen monthly for all compensation earned and pass-through
costs incurred for that month. All invoices shall be payable within 30 days of
receipt. Further, PPD shall invoice Introgen for all additional
performance-based compensation earned by meeting one or more milestones
described in Section 2.2 when all of PPD's services under this Project Addendum
are completed or after this Project Addendum is terminated without default by
PPD, which invoices will also be paid within 30 days of receipt.

     2.3 - Payments to PPD shall be made to:

               FOR [*]                        FOR [*]
               ---------------------          ----------
               [*]                            [*]

or if wired:   [*]

3.   STANDARD OPERATING PROCEDURE
     ----------------------------

     PPD shall conduct the Study according to Section 2.1 of the Agreement.
Upon mutual agreement in writing, the parties may conduct the Study under
Sponsor's standard operating procedures. In such case, Sponsor shall provide
prompt and reasonable training to any PPD personnel subject to such SOPs at
Sponsor's expense.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                          Page 4
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

4.   TERM AND TERMINATION.
     ---------------------

     The term of this Project Addendum shall commence on the Effective Date and
end upon the completion of Services unless otherwise terminated in accordance
with the Agreement.

5.   INCORPORATION BY REFERENCE/CONFLICT OF TERMS.
     ---------------------------------------------

     The terms and conditions of this Project Addendum and Exhibits hereto are
hereby incorporated into and made a part of the Agreement. To the extent any
terms contained in an Exhibit hereto conflict with this Project Addendum, the
terms of this Project Addendum shall control. In the event of any inconsistency
between the Agreement, the Project Addendum and the Protocol, the terms of the
Protocol shall govern first, followed by the Project Addendum and then by the
Agreement unless otherwise specified.

6.   MODIFICATIONS.
     --------------

     Any changes to this Project Addendum or its Exhibits shall be documented
by written Amendments upon approval by both parties and shall be attached
hereto. No Amendment will bind Introgen unless it is signed by an Introgen
officer at the level of vice president or higher.

Remainder of this page intentionally left blank

--------------------------------------------------------------------------------
                                                                          Page 5
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

7.   NOTICES.
     --------

     Persons set forth below shall have the authority to make executive
decisions regarding this contract. Any notice required or permitted to be given
hereunder by either party hereunder shall be in writing and shall be deemed
given on the date received if delivered personally or by fax or five (5) days
after the date postmarked if sent by registered or certified U.S. mail, return
receipt requested, postage prepaid to the following address:

     If to PPD:          PPD Development, LLC
                         3151 17th Street Extension
                         Wilmington, North Carolina 28412
                         Attention: Dr. Paul Covington
                         Tel: (910) 251-0081
                         Fax: (910) 762-5820

     If to Sponsor:      Introgen Therapeutics, Inc.
                         2250 Holcombe Blvd.
                         Houston, Texas 77030
                         Attention: Vice President, Operations
                         Tel: (713) 797-9960
                         Fax: (713) 797-9913

                         With copy to:
                         Introgen Therapeutics, Inc.
                         301 Congress, Suite 1850
                         Austin, TX 78701
                         Attention: Chief Financial Officer
                         Tel: (512) 708-9310
                         Fax: (512) 708-9311

8.   PPD GLOBAL LTD.
     ---------------

     It is noted that, although it is named as a party to the Agreement, PPD
Global Ltd. did not sign the Agreement. By signing this Project Addendum, PPD
Global Ltd. and PPD Development LLC ratify the Agreement, acknowledge that all
time since its signature by PPD Development LLC on July 20, 2001, PPD Global
Ltd. has been a party to the Agreement, and confirm that PPD Development LLC
and PPD Global Ltd. are jointly and severally responsible for performance of
all obligations of either of them under the Agreement and this Project Addendum.

--------------------------------------------------------------------------------
                                                                          Page 6
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

<Table>
<Caption>
PPD DEVELOPMENT, LLC                         INTROGEN THERAPEUTICS, INC.
<S>                                          <C>
By:    /s/ Paul S. Covington, M.D.           By:    /s/ J. David Enloe, Jr.

Name:  Paul S. Covington, M.D.               Name:  J. David Enloe, Jr.

Title: Sr. VP Medical Affairs/CSO            Title: Vice President of Operations

Date:  17 December 2001                      Date:  ____________________________

PPD GLOBAL, LTD.

By:    /s/ Paul S. Covington, M.D.

Name:  Paul S. Covington, M.D.

Title: Sr. VP Medical Affairs/CSO

Date:  17 December 2001

</Table>

    APPROVED
  MC 12/17/01
 PPD CONTRACTS

--------------------------------------------------------------------------------
                                                                          Page 7
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                  EXHIBIT A.1

                           [*] PROJECT CONSIDERATIONS

-  PPD Development assumes that this project will be conducted according to PPD
   Development's Standard Operating Procedures (SOPs) and Working Practice
   Documents (WPDs). If Introgen chooses to use their own SOPs and WPDs,
   Introgen will assume responsibility for training the PPD Development team on
   all applicable SOPs and WPDs.

-  PPD Development has assumed a monitoring frequency of [*] during the
   enrollment, treatment and follow-up of this trial. We have assumed
   approximately [*] on site for interim monitoring visits at those sites
   participating in either the T-301 trial or the T-302 trial. If a site is
   participating in both the T-301 and T-302 trials, we have assumed a [*]
   monitoring visit.

-  PPD Development has assumed that a staff of [*] and a Project Manager (PM)
   will be necessary once all sites are open and enrolling until [*], at which
   time there will be a staff of [*]. PPD Development anticipates that the
   current team of [*] and [*] PM will remain on the trial until the end of [*]
   and then an additional [*] will be added to the team once the entire group of
   sites is open for enrollment.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                          Page 8
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                             PROJECT SPECIFICATIONS

PROTOCOL TITLE:
A Phase III, Multicenter, Open-Label, Randomized Study to Compare the Overall
Survival and Safety of Bi-Weekly Intratumoral Administration of RPR/INGN 201
Versus Weekly Methotrexate in Patients with Refractory Squamous Cell Carcinoma
of the Head and Neck.

                              STUDY SPECIFICATIONS
<Table>
<S>                                          <C>
Protocol Number and Compound                 T301 and T302

Introgen Contact                             [*]

PPD Development Contact                      [*]
                                             Manager, Business Development

Indication                                   Head and Neck Cancer

Program Phase                                III

Study Design                                 Open-label

Number of Enrolled/Randomized Patients       [*] Patients in T301 and [*] Patients in T302
                                             for a Total of [*]

Number of Completed Patients                 [*]

Number of Investigators                      [*]

Approximate Number of Patients Per Site      [*]

Enrollment Period                            [*] Months

Enrollment Rate                              [*] Patients/Site/Month

Type of IRB                                  Local

Duration of Patient Participation            [*] Months

Interim Monitoring Frequency                 Every [*] Months

Time on Site                                 [*] Day

Number of Initiation Visits                  [*] ([*] for T301 and [*] for T302)

Number of Interim Visits                     [*] for T301 and [*] for T302

Number of Close-Out Visits                   [*] ([*] for T301 and [*] for T302)
</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                          Page 9
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

     -----------------------------------------------------------------------
     Case Report Forms per Patient      [*]/Patient -- [*] Total for T301
                                        [*]/Patient -- [*] Total for T302
     -----------------------------------------------------------------------
     Unique Case Report Form            [*] for T301 and T302
     -----------------------------------------------------------------------
     Deliverable                        Lockable Database
     -----------------------------------------------------------------------

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 10
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                PROJECT TIMELINE

                           Project Milestone Periods

The program timeline is summarized in the table below.

<Table>
<Caption>
           ACTIVITY                          DURATION*
           --------                          --------
     <S>                                     <C>
     Enrollment Period                       [*] Months

     Treatment Period                        [*] Months

     Study Close-out                         [*] Months

     Total PPD Development Commitment        [*] Months
</Table>

* Some activities may overlap

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 11
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                 PROJECT TEAMS

-   Clinical Project Team

    Upon execution of this Project Addendum, PPD will commit [*] Project Manager
    and [*] clinical research Associates on a full time basis for both
    studies. Initially, the following individuals will occupy such positions:

               Project Manager:         [*]
               CRA:                     [*]
               CRA:                     [*]
               CRA:                     [*]
               CRA:                     [*]
               CRA:                     [*]

    Effective March 1, 2002, the number of CRAs will be increased to [*]
    full time individuals, with the newly added personnel to be subject to
    approval in writing by Introgen. The Project Manager and all of the CRAs
    will work full time (generally at least [*] hours per day, [*] days
    per week) on the Studies which are the subject of this Project Addendum, to
    the exclusion of work for any other PPD clients or projects. Any PPD
    Development employee will be removed from the project and replaced with a
    suitable replacement upon request by Introgen, with or without cause.

    Should the proposal assumptions change, staffing will be reviewed and
    modified accordingly, after appropriate discussions with Introgen, but only
    with Introgen's written consent. Such consent shall not be unreasonably
    withheld.

    European personnel will not work full time on the studies, but will be
    assigned by PPD at a level sufficient to complete the project in a timely
    manner.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 12
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                            DESCRIPTION OF SERVICES

PROTOCOL

-    PREPARATION OF PROTOCOL

     The final study  protocol has been completed for this study. Introgen will
     be responsible for the preparation of any amendments to the final study
     protocol. Should assistance be required, PPD Development has an experienced
     team of individuals who are available to provide protocol
     preparation/finalization for Introgen.

-    INFORMED CONSENT

     A draft Informed Consent form containing all required elements had been
     reviewed and approved prior to submission to Ethics Committees by the
     Investigator.

CASE REPORT FORMS (CRFs)

-    CRF DESIGN

     CRFs have been designed and drafted for protocols T301 and T302. The CRFs
     are designed to capture all pertinent information in a format that allows
     for rapid review and data entry.

-    PRINT CRF

     The CRFs have been printed on NCR paper and shipped to the investigator
     sites prior to initiation of the study.

--------------------------------------------------------------------------------
                                                                         Page 13
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

SITE/INVESTIGATOR IDENTIFICATION AND QUALIFICATION

SITE/INVESTIGATOR IDENTIFICATION

PPD Development maintains an active Investigator Recruitment Database
(IRDB(TM)) consisting of more than [*] investigators worldwide. The
information collected on each investigator includes: site demographics,
professional profile, specialty certifications, research profile, staff
personnel, facilities on site, data management experience, practice setting,
research experience/interest and previous clinical trial experience. Post study
evaluations are also on file for investigators who have worked with PPD
Development. These evaluations are completed by the study Monitor and the
Project Manager. This is a dynamic database that is continually expanded and
updated. It is from this database, as well as from Introgen Therapeutics, Inc.
lists and other external sources, that PPD Development will derive a list of
potential investigators for any particular study. PPD Development will work
closely with Introgen on all aspects of identifying the most appropriate
investigators.

Some of the areas of physician specialty and the number of investigators in
PPD's database include: Allergy/Immunology [*]; Anesthesiology [*]; Cardiology
[*]; Dermatology [*]; Endocrinology [*]; Family Practice [*]; Gastroenterology
[*]; Geriatric Medicine [*]; Infectious Disease [*]; Internal Medicine [*];
Medical Oncology [*]; Neurology [*]; OB/GYN [*]; Orthopedic Surgery [*];
Pediatrics [*]; Psychiatry [*]; Surgery [*]; and Urology [*].

The type and number of practice settings include: University Hospital [*];
Other Hospital [*]; Private, Solo, Group and Multi-Specialty combined [*];
Nursing Home [*]; VA/Military [*]; TMO [*]; Study Health Center [*]; Urgent Care
Center [*]; Rehabilitation Hospital/Clinic [*]; Mental Health Retardation [*];
Managed Health Care [*]; and Surgical Care [*].

PPD Development will assist in identifying investigators with a proven clinical
study record in managing and overseeing this type of clinical trial.
Investigators will be chosen on their ability to produce both the necessary
patient population and the appropriate study staffing. Upon Introgen's
approval, PPD Development will select [*] sites to participate in the study.
Each site will recruit approximately [*] patients during the [*] months of
anticipated enrollment, an average of [*] patients per site per month. These
sites will be located in USA and ceratin European countries; however, no
estimation of site distribution has been determined at this time.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 14
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

--   SELECT STUDY SITE/INVESTIGATORS

     Clinical Research Associates on the project team will conduct
     comprehensive, on-site visits to further evaluate the investigative site,
     meet with the study personnel, review the protocol, develop the patient
     recruitment plan, visit all the facilities required by the protocol and
     review any other site qualifications deemed critical to the successful
     completion of the study. The evaluator will then make final recommendations
     to the project team.

     The success of most programs is dependent upon the ability to identify the
     most qualified investigators who will be able to enroll a sufficient number
     of patients who meet criteria as specified by the study protocol and to
     provide quality data. PPD Development, in collaboration with Introgen, will
     use reasonable efforts and due diligence to ensure that each investigator
     selected is qualified to perform the services required.

--   SITE QUALIFICATION VISITS

     When the list of potential investigators has been compiled and passed
     through appropriate review by project management and Introgen, PPD
     Development Clinical Research Associates will begin the process of
     recruiting the investigators. Rigorous telephone screening of potential
     investigators is performed by Clinical Research Associates prior to the
     on-site evaluation visits to determine their interest in, and suitability
     for, performing the study. These telephone calls to prospective sites will
     allow an initial screening via assessment of critical factors such as
     availability, staff, facilities, patient population and clinical trial
     experience in the appropriate therapeutic area.

     PPD Development will perform the site qualification visits. The purpose of
     each visit is to assess the study facilities, the staff and the Principal
     Investigator for actual protocol competency. During the visit, the PPD
     Development project team will ensure the following:

     --   The Principal Investigator's expertise
     --   The availability of knowledgeable support staff
     --   The adequacy of the facility to conduct a clinical trial
     --   The availability of the appropriate subject population
     --   The Principal Investigator's understanding of the regulatory
          obligations as outlined on the FDA form 1572 or equivalent and
          specified by Introgen and PPD Development

     Additional site qualification visits necessary to reach the project of a
     total of 100 active sites will be conducted by PPD Development. Written
     trip reports will be prepared and submitted to Introgen within two weeks of
     each visit.

--   INVESTIGATOR GRANTS COORDINATION

     PPD Development will, in accordance with the investigator contract
     previously approved by Introgen, make all necessary payments to the
     investigators. Prior to payment, the Project

--------------------------------------------------------------------------------
                                                                         Page 15
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

     Manager will verify the patient enrollment status at the site to ensure all
     payments are accurate and reflective of study site activity.

PRE-STUDY ACTIVITIES

-    REGULATORY DOCUMENT COLLECTION

     PPD Development will collect, review and approve all regulatory documents
     required under the United States Code of Federal Regulations (CFR) or
     equivalent laws and regulations of each non-U.S. country for each
     participating investigator. Critical documents for each site include the
     following:

     -    Protocol agreement page

     -    IRB or equivalent approval letter together with a list of IRB or
          equivalent members

     -    Copy of the IRB or equivalent approved informed consent form to be
          used in the study

     -    Signed FDA Form 1572 or equivalent

     -    Curriculum vitae for the principal and sub-investigators

     -    Laboratory certification and normal values

     -    Financial Disclosure Agreements

     -    Other documents required by the laws and regulations of the relevant
          country.

     Regulatory packets will be assembled and delivered to Introgen. Introgen
     shall submit all regulatory packets to the FDA or equivalent. Once the
     appropriate regulatory documents have been submitted to the FDA or
     equivalent, then Introgen will authorize shipment of the study drug to
     each individual site.

-    CENTRAL LABORATORY COORDINATION

     If a central laboratory is necessary for this study, it will be selected
     by Introgen.

--------------------------------------------------------------------------------
                                                                         Page 16

<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------
*STUDY DRUG MANAGEMENT

 Introgen will design and print labels, label and secondary package, distribute,
 store, perform analytical services. PPD Development will perform return
 accountability and destroy the study drug or return the study drug to Introgen.
 At the conclusion of the study or as requested, a complete accountability
 report will be provided to Introgen. The accountability report will contain
 at least the following information:

 Site # and investigator name
 Patient # and initials
 Date dispensed, quantity dispensed
 Initials of person dispensing study drug

*SPONSOR MEETINGS

 PPD Development anticipates a total of 18 Introgen Therapeutics, Inc. meetings
 will be held throughout this study. It is estimated that approximately three
 PPD Development project team members will attend these meetings. Travel costs
 for these meetings will be billed as Pass-through Indirect Costs. Such travel
 shall be conducted in accordance with PPD Development travel policy.

STUDY INITIATION

*SITE INITIATION VISITS

 PPD Development will perform an initiation visit at each site. The following
 areas will be reviewed with site personnel during the initiation visit:

 *Background information, including the Investigator Brochure for the study
   drug and/or the product package insert(s)

 *Protocol, study procedures and associated forms

 *Interim monitoring visit schedule

 *Regulatory requirements

 *Planned enrollment rates, initiation dates and completion dates

 *CRF and source documentation

 *CRF completion instructions

 *Adverse event reporting

 *Study drug accountability

 Training of all relevant site personnel will occur at this visit and on an
 ongoing basis throughout the trial. Introgen agrees that training shall be the
 primary responsibility of PPD Development.

--------------------------------------------------------------------------------
                                                                         Page 17
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

     A total of 111 (60+51) initiation visits will be conducted for these
     studies. Trip reports will be prepared within two weeks after each visit
     and sent to Introgen.

PROJECT MANAGEMENT

-    PROJECT MANAGEMENT

     The Project Manager's responsibilities will include managing the technical
     and administrative aspects of the study as defined by Introgen. The Project
     Manager will coordinate the organization, implementation and management of
     the study. In addition, the Project Manager will interact directly with the
     Clinical Project Director, Medical Director, Project CRAs, Compliance
     personnel, Data Management personnel and Biostatistics personnel (all of
     whom are PPD employees) to ensure the effective and timely completion of
     the study.

     The Project Manager will also perform the following project-specific
     activities:

     -    Project planning

     -    Preparation of the Study Operations Manual

     -    Coordination and assistance with personnel training

     -    Coordination of the investigators' meeting, to include travel and
          agenda planning

     -    Provision of monthly status reports to include:

          -    Regulatory document collection
          -    Site start-up status
          -    Enrollment status
          -    Monitor visit reports
          -    Site drug inventories
          -    Serious Adverse Events (SAEs)
          -    Number of CRFs retrieved

     -    Review and sign timesheets, expense reports and travel authorizations

     -    Review project staffing and utilization, travel itinerary, trip
          reports, external correspondence and telephone reports, internal
          correspondence, follow-up letters and monthly travel calendars/plans

     -    Assure all tracking logs are updated weekly by the CRAs

     -    Facilitate all financial and contractual matters between Introgen and
          PPD Development (i.e., prepare study-specific invoices for payment at
          milestones met by PPD Development)

--------------------------------------------------------------------------------
                                                                         Page 18
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

ON-SITE MONITORING

-  ON-SITE MONITORING

   PPD Development will perform all interim monitoring visits for this study,
   with the exception of [*], which will be monitored by Introgen. Given the
   anticipated study length of [*] months per patient, an enrollment period of
   [*] months and a monitoring frequency of every [*] months, PPD Development
   will be required to perform approximately [*] interim monitoring visits of
   [*] duration per site. The CRA will perform the following tasks during each
   interim visit:

   -  Compare 100% of the CRFs to the source documents

   -  Review the CRFs and source documents for serious adverse events

   -  Resolve queries

   -  Perform drug accountability

   -  Ensure appropriate signed informed consent exists for each study
      participant

   -  Review investigator study files for completeness

   -  Ensure investigator compliance to the study protocol

   A total of [*] interim monitoring visits will be conducted. Trip reports will
   be prepared and provided periodically to Introgen as agreed.

-  CLOSE-OUT VISITS

   A final close-out visit will be conducted after all subjects have completed
   or have been discontinued from the study and after all queries have been
   resolved. Each visit will include:

   -  Review and retrieval of all outstanding CRFs

   -  Study drug accountability and preparation for the shipment of study drug
      to Introgen

   -  Review of investigator's study file for completeness

   -  Review of record retention per FDA or other regulatory requirements

   A total of [*] close-out visits will be performed for these studies.
   Close-out visit reports will be prepared within two weeks after each visit
   and sent to Introgen.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 19
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

-  TOTAL NUMBER OF SITE VISITS T301

<Table>
<Caption>
SITE VISIT          NUMBER PER SITE          TOTAL
<S>                 <C>                      <C>
Qualification          [*]                       [*]
Initiation             [*]                       [*]
Interim Monitoring     [*]                       [*]
Close-Out              [*]                       [*]
TOTAL                  [*]                       [*]
</Table>

-  TOTAL NUMBER OF SITE VISITS T302

<Table>
<Caption>
SITE VISIT          NUMBER PER SITE          TOTAL
<S>                 <C>                      <C>
Qualification          [*]                       [*]
Initiation             [*]                       [*]
Interim Monitoring     [*]                       [*]
Close-Out              [*]                       [*]
TOTAL                  [*]                       [*]
</Table>

SITE MANAGEMENT

-  IN-HOUSE SITE MANAGEMENT BY CLINICAL PROJECT TEAM

   Between monitoring visits, investigators will be called weekly to verify
   patient enrollment status, review study progress, answer protocol questions,
   discuss CRF completion and ensure the study proceeds in a timely manner. Site
   contact reports will become part of the investigator file located at PPD
   Development. Additionally the PPD Development CRAs will be responsible for:

   -  Tracking and ordering study drug and other supplies

   -  Tracking regulatory document revisions

   -  Writing trip reports

   -  Writing follow-up letters

   -  Providing query resolution

   -  Performing in-house second review of CRFs

   -  Participating in scheduled conference calls with Introgen

   -  Tracking protocol violations, CRF progression at site and PPD Development
      and tracking of query resolution

   -  Conducting audit of investigator files at PPD Development

   -  Developing newsletter materials and distributing newsletter to sites

   PPD Development will be responsible for all follow-up on action items
   identified during the monitoring visits.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 20
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

-    CLINICAL REVIEW OF CRFs AND QUERY RESOLUTION

     The CRF will be forwarded to the Clinical Project Manager who will evaluate
     the following elements:

     - Accurate and appropriate documentation of adverse events ("AEs")
     - Overall subject study drug and protocol compliance
     - Proper identification and documentation of potential protocol deviations
       or violations
     - Accurate completion of inclusion/exclusion criteria
     - Accurate transcription of CRF data
     - Appropriate use of medical terminology
     - Correlation of all clinical information
     - Accuracy of any medication dosages

DATA MANAGEMENT

-    DATA MANAGEMENT PLAN

     The PPD Clinical Data Management (CDM) Project Leader/Manager will compile
     a Data Management Plan that describes the processes and specifications to
     be used in the project. This includes documentation on the data
     dictionaries to be used; the logic and processes for data review and
     validation; critical timelines and milestones; and timing and types of
     management reports. This Plan will be reviewed and finalized and will be
     updated during the course of the project.

-    DATABASE DEVELOPMENT

     The project database will be set up using PPD Development's established
     data management systems. PPD Development will develop the specifications
     for this database following a review of the protocol, CRFs and PPD
     Development's previous experience with the Introgen studies. Database
     specifications will be independently reviewed by PPD Development prior to
     installation. PPD Development will submit the database specifications to
     Introgen for approval if requested.

-    DOCUMENT MANAGEMENT

     CRFs will be forwarded from each investigational site or by the study
     monitors to the PPD Development Document Management team. Each CRF will be
     entered into a tracking system and followed throughout the entire process.

--------------------------------------------------------------------------------
                                                                         Page 21
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

-    DATA ENTRY

     Data entry screens will be developed based on the study CRF and database
     requirements. The entry of the data from each CRF into the database will
     take place as CRFs are retrieved, to keep the database as current as
     possible. All data entry discrepancies will be resolved by PPD Development
     Data Management staff. Reports regarding data entry status and the database
     will be available as needed.

-    DATA VALIDATION

     Validation (edit) checks and derivation procedures will be developed by PPD
     Development using PL/SQL, SQL, RPL or SAS procedures. The validation
     specifications will be developed taking into account the requirements of
     the analysis plan, a review of the protocol and general experience. The
     validation specifications will be forwarded to Introgen for review and
     approval. The results from the validation process will be reviewed and
     queries will be generated for resolution.

-    IMPORTING ELECTRONIC DATA

     Electronic data from central laboratories and any associated ranges will be
     imported and integrated into the study database. PPD Development will
     provide validation checks as required and issue queries as part of the data
     review and validation process.

-    CODING OF DRUGS AND DISEASES

     Unless otherwise requested by Introgen, PPD Development will provide the
     coding dictionaries required for coding adverse events and concomitant
     medications. WHOART and COSTART will be used to code adverse events and
     WHODRUG will be used to code concomitant medications. If necessary,
     Introgen coding dictionaries can also be used.

     PPD Development will use its ORACLE-based auto-encoding system to identify
     appropriate codes and insert them into the appropriate tables. The PPD
     Development auto-encoding system maintains a synonym dictionary so as not
     to compromise Introgen dictionaries. This synonym dictionary also contains
     multi-lingual coding translations. Efficient support of international and
     cross-national coding schemes is provided. Validation checks on the synonym
     code lists can be imposed to ensure that coding meets Introgen criteria.
     Coded terms can be sent to Introgen for routine review. A final clinical
     review by PPD Development will be conducted of all codes to ensure accuracy
     and consistency.

--------------------------------------------------------------------------------
                                                                         Page 22
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

- DATA QUERY RESOLUTION

  Queries arising from data entry, validation and dictionary coding will be
  reviewed and, if possible, resolved by Data Management personnel, according to
  the rules documented in the Data Management Plan. Where necessary, queries
  will be passed to CRAs for resolution or forwarded to the investigator. Review
  and correction of data will occur on an ongoing basis. Queries and corrections
  will be tracked electronically for each CRF.

- STATUS REPORTS

  PPD will provide Introgen with standard monthly status reports indicating the
  progress made on the project. This report can be customized to meet Introgen
  specifications. The report will include such information as number of patients
  entered, number of completed patients, number of ongoing patients and metrics
  on key processes.

- SPONSOR ACCESS TO DATABASE

  At Introgen's option, PPD Development will set up a link to allow Introgen
  browsing access to the clinical data at additional mutually agreeable costs.
  This access will be accomplished using secure telecommunications with specific
  software. This option will allow browsing of the clinical database and
  creation of ad hoc data reports. PPD Development will work with Introgen to
  set up a study specific process for the access so that the material being
  reviewed by Introgen is well defined.

- DATA MANAGEMENT QUALITY CONTROL

  To ensure accuracy, PPD Development will conduct a [*] verification of the
  CRF against the database for randomly selected [*] sample of the patients
  through the study. In addition, various patient listings will also be produced
  and reviewed to assure data quality and consistency.

- DATABASE FINALIZATION

  As required by the study and identified in the Data Management Plan, key
  safety and efficacy variables will be [*] reviewed. A final quality control
  check will be performed on [*] of the patients on the final database after all
  data has been entered and all queries resolved. A written report of this check
  will be prepared and sent to Introgen reporting discrepancies that are found.

  PPD Development will return  to Introgen the database in a SAS format. The
  program code for data validations will remain with PPD at the conclusion of
  the study. CRFs and supporting documentation will be returned to Introgen at
  the conclusion of the project.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 23
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

-    QUALITY ASSURANCE

     PPD Development's Quality Assurance (QA) department will be informed when a
     database lock has occurred. In such event, QA will perform an audit to
     review the Quality Control (QC) procedures used during the conduct of the
     study to ensure that SOPs, Working Practices and project specific plans
     have been followed. The database error rates will be reviewed to ensure
     that acceptable quality as defined in the study plan have been achieved.

-    DATA TRANSFERS

     FORMAT AND TEST. PPD Development will require data transfer specifications
     (i.e., file layouts, formats) before initiating program development for
     data transfers. We recommend at least [*] preliminary transfer to test the
     transfer mechanism prior to the final database transfer. PPD Development
     will be required to transfer the study database [*] times for each project.
     On protocol T301, this will include [*] test transfer, [*] interim data
     transfer after the first [*] patients have completed [*] months on study,
     [*] DSMB transfer, and [*] final transfer. The interim transfers will have
     clean safety and efficacy data. Clean is defined as all first round queries
     run and updated and data is coded.

     On Protocol T302, the transfers will include [*] test transfer, [*] interim
     transfer after the first [*] patients have completed [*] months of
     treatment, [*] DSMB transfers and [*] final transfer. The interim transfers
     will have clean safety and efficacy data. Clean is defined as all first
     round queries run and updated and data is coded.

     PPD Development will provide Introgen with SAS files containing the project
     database along with complete documentation.

-    ALTERNATIVE TECHNOLOGIES

     PPD Development has experience with a variety of alternative technologies,
     (e.g., remote data capture, imaging). PPD Development welcomes further
     discussion of data management operational strategy to meet the needs of
     Introgen.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 24
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

DATA MANAGEMENT WORK FLOW

                                Data Management
                                     Set-Up

                                 CRF's Received

                                  CRF's Tracked
                                Pre-Entry Review

                             Independent Dual Entry
                                      Edit
                                  Verification

                              Execute Tag Listings
                             Resolve Discrepancies
                                  Remove Flags

                                  QC Validate
                              Manual Link Lab Data
                                     Review

                              Resolve Outstanding
                                    Queries
                            Code Drugs and Diseases

                                Merge Data Table

                                    Final QC

                             DBA Revokes Privileges
                               (Locked Database)

                             Deliver Final Database

--------------------------------------------------------------------------------
                                                                         Page 25

<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                             STATEMENT OF SERVICES
                                   T301/T302
The following lists the specific responsibilities assigned to Introgen (x) or
PPD Development (x).
<Table>
<S>                                                      <C>              <C>
                                                                               PPD
                    TASK LIST                             INTROGEN         DEVELOPMENT
A.   PROTOCOL
1.   Design study                                           [*]                [*]
2.   Write protocol                                         [*]                [*]
3.   Approve protocol                                       [*]                [*]
4.   Prepare template informed consent                      [*]                [*]
B.   CASE REPORT FORM (CRF)
1.   Design and draft CRFs                                  [*]                [*]
2.   Finalize CRFs                                          [*]                [*]
3.   Print and bind CRFs                                    [*]                [*]
4.   Distribute CRFs to sites                               [*]                [*]
5.   Write CRF instruction guide                            [*]                [*]
C.   SITE/INVESTIGATOR IDENTIFICATION AND QUALIFICATIONS
1.   Develop list of potential sites                        [*]                [*]
2.   Select study sites/investigators                       [*]                [*]
3.   Conduct site qualification visits                      [*]                [*]
4.   Provide written site evaluation reports                [*]                [*]
5.   Discuss grant payments and contract with sites         [*]                [*]
6.   Negotiate investigator grants, LOA, LOI                [*]                [*]
7.   Prepare investigator contract                          [*]                [*]
8.   Prepare indemnification/liability statement            [*]                [*]
D.   PRE-STUDY ACTIVITIES
1.   Collect regulatory documents (CVs, IRB approval,       [*]                [*]
     FDA 1572)
2.   Obtain IRB approval                                    [*]                [*]
3.   Review and evaluate for completeness all elements      [*]                [*]
     of informed consents for all sites
4.   Contract with central laboratory                       [*]                [*]
5.   Set up project tracking system via RTMS(TM)            [*]                [*]
E.   TEST ARTICLE MANAGEMENT
1.   Supply study drug/device                               [*]                [*]
2.   Package study drug/device                              [*]                [*]
3.   Label study drug/device                                [*]                [*]
4.   Distribute study drug/device to site                   [*]                [*]
5.   Store study drug/device                                [*]                [*]
6.   Develop drug/device accountability log                 [*]                [*]
7.   Manage drug/device accountability records              [*]                [*]
8.   Perform post-study study drug/device accountability    [*]                [*]
9.   Return unused supplies/study drug/device to Introgen   [*]                [*]

</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 26
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------
<Table>
<Caption>
                                                                         PPD
          TASK LIST                               INTROGEN           DEVELOPMENT
<S>                                           <C>                 <C>
F. RANDOMIZATION SERVICES
1. Provide randomization scheme                      [*]                  [*]
2. Provide central computerized
   randomization (IVR--touch-tone system)            [*]                  [*]
3. Provide central attended randomization            [*]                  [*]
4. Provide at-site randomization envelopes           [*]                  [*]
G. COMMUNICATIONS MANAGEMENT
1. Attend project meetings                           [*]                  [*]
H. INVESTIGATORS' MEETING(S)
1. Plan investigators' meeting(s)                    [*]                  [*]
2. Prepare start-up information binders              [*]                  [*]
3. Approve start-up information binders              [*]                  [*]
4. Conduct investigators' meeting(s)                 [*]                  [*]
5. Present at investigators' meeting(s)              [*]                  [*]
I. STUDY INITIATION
1. Conduct site initiation visits                    [*]                  [*]
2. Provide and maintain training of
   site personnel                                    [*]                  [*]
3. Review source documents--CRFs,
   drug records, etc.                                [*]                  [*]
J. PATIENT RECRUITMENT
1. Develop and execute advertising plan              [*]                  [*]
2. Refer potential patients to sites                 [*]                  [*]
K. PROJECT MANAGEMENT
1. provide weekly updates via RTMS(TM)               [*]                  [*]
2. Contribute study information for
   monthly newsletter                                [*]                  [*]
3. Select central laboratory                         [*]                  [*]
4. Coordinate with central laboratory                [*]                  [*]
5. Establish and maintain 24 hour SAE
   phone line                                        [*]                  [*]
6. Administer investigator payments                  [*]                  [*]
7. Develop/maintain protocol deviation
   database                                          [*]                  [*]
8. Train the project team                            [*]                  [*]
L. ON-SITE MONITORING
1. Conduct interim on site monitoring visits         [*]                  [*]
2. Review and verify 100% of available source
   documentation on all CRFs                         [*]                  [*]
3. Obtain corrections to CRFs/query
   resolution                                        [*]                  [*]
4. Review drug records                               [*]                  [*]
5. Verify investigators' compliance with
   protocol and regulatory requirements              [*]                  [*]
6. Maintain site training of personnel               [*]                  [*]
7. Conduct study close-out visits                    [*]                  [*]
8. Provide written site monitoring reports           [*]                  [*]
</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 27
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

<Table>
<Caption>
                                                                               PPD
                    TASK LIST                             INTROGEN         DEVELOPMENT
<S>                                                      <C>              <C>
M.   SITE MANAGEMENT
1.   Maintain phone log of clinical questions                 [*]              [*]
2.   Maintain phone log of questions regarding CRFs/logistics [*]              [*]
3.   Participate in scheduled conference calls                [*]              [*]
4.   Provide document control of CRFs - log, track, archive   [*]              [*]
5.   Perform clinical review of CRFs                          [*]              [*]
6.   Perform records management                               [*]              [*]
7.   Enter and verify data                                    [*]              [*]
N.   DATA MANAGEMENT SET-UP
1.   Design data collection system                            [*]              [*]
2.   Develop data collection system                           [*]              [*]
3.   Validate data collection system                          [*]              [*]
4.   Design data cleaning system                              [*]              [*]
5.   Develop data cleaning system                             [*]              [*]
6.   Validate data cleaning system                            [*]              [*]
7.   Provide drug dictionary                                  [*]              [*]
8.   Provide adverse event dictionary                         [*]              [*]
O.   DATA ENTRY
1.   Initial review of CRFs                                   [*]              [*]
2.   Document management of CRFs - log, track, archive        [*]              [*]
3.   Enter and verify data                                    [*]              [*]
P.   DATA MANAGEMENT
1.   Run data cleaning system                                 [*]              [*]
2.   Resolve queries generated                                [*]              [*]
3.   Document corrections to CRFs                             [*]              [*]
4.   Perform data management audits                           [*]              [*]
5.   Code concomitant drugs                                   [*]              [*]
6.   Code adverse events                                      [*]              [*]
7.   Integrate/merge electronic data                          [*]              [*]
Q.   DATA TRANSFERS
1.   Format data according to Introgen format (SAS datasets)  [*]              [*]
2.   Test data transfer                                       [*]              [*]
3.   Interim analysis data transfer(s)  Number: 1             [*]              [*]
4.   Final data transfer                                      [*]              [*]

</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 28

<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------
                                     [*]

                    PROJECT SPECIFICATIONS FOR T-301 & T-302

The following key assumptions have been used to provide costs for Introgen.
These are based on the previous communication with PPD Development and Introgen,
our experience with the studies PPD Development is performing in [*] and our
best estimates based on our extensive experience in performing and managing
clinical studies.

Should any details change then PPD Development will review and amend these
budgets as appropriate.

GENERAL ASSUMPTIONS
<Table>
<S>                                     <C>                    <C>
STUDY                                         T-301                    T-302
Number of Screened Patients                    [*]                      [*]
Number of Patients Entering trial              [*]                      [*]
Number of Evaluable Patients                   [*]                      [*]
Participating Countries/Sites
                                               [*]                      [*]
This is just a basic assumption at             [*]                      [*]
present and will be updated when               [*]                      [*]
information is available                       [*]                      [*]
Number of CRF pages per Enrolled
Patient*                                       [*]                      [*]
Number of CRF pages per Screened
Patient                                        [*]                      [*]
Investigators' Meeting                         [*]                      [*]
Enrolment Period                               [*]                      [*]
Treatment Period                               [*]                      [*]
Number of Patient visits                       [*]                      [*]
Number of Client Meetings
Includes pre June tel conf and                 [*]                      [*]
hand over meeting
Number of Project Team Meetings
Include 2 day monitors meeting                 [*]                      [*]
Number of Conference Calls                     [*]                      [*]

</Table>

*    PPD Development understand that total number of CRF pages is [*]
     has been used to account for the high patient death rate that will affect
     the patient completion rate.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 29
<PAGE>
                                                               Project Addendum
--------------------------------------------------------------------------------

CLINICAL/MEDICAL ASSUMPTIONS

We have assumed that all sites will require either a hand-over site visit with
the Introgen CRA and in some cases this will be the site initiation visit. PPD
Development will be negotiating and coordinating Investigator payments. No
investigator meetings will be required for either study for the purpose of this
costing. PPD Development would be happy to provide costs for investigator
meetings later should Introgen wish to hold further meetings.

<Table>
<Caption>
STUDY                                   T-301                    T-302
<S>                                  <C>                       <C>
Number of protocol
summaries/ICON Translations              [*]                      [*]
Number of Sites Identified               [*]                      [*]
Number of Pre-study evaluation
visits                                   [*]                      [*]
Number of Initiation/Hand-Over
Visits                                   [*]                      [*]
Interim Monitoring Frequency             [*]                      [*]
Total Number of Interim Visits/
site                                     [*]                      [*]
Duration of Monitoring visit (Av.)       [*]                      [*]
Number of Close-Out Visits               [*]                      [*]
% Source Data Verification               [*]                      [*]
Number of QA Site Audits                 [*]                      [*]
Anticipated Number of SAEs               [*]                      [*]
Frequency of Investigator
Payments                                 [*]                      [*]

</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 30

<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                PROJECT TIMELINE

The program timeline is summarized in the table below;
<Table>
<Caption>
               ACTIVITY                 TIMETABLE                   TIMETABLE
                                          T-301                       T-302
<S>                            <C>                         <C>
Start of PPD Activity                      [*]                         [*]

Study Hand Over Meeting                    [*]                         [*]

Enrollment Period                          [*]                         [*]
                                                                       [*]
Treatment/Follow-up                        [*]                         [*]
Period

Site Close-Out Visits                      [*]                         [*]

TOTAL PPD DEVELOPMENT
COMMITMENT                                 [*]                         [*]

</Table>

These timelines are subject to:

-    Introgen providing all the necessary documentation and information in
     sufficient time for the hand-over process to begin [*].

-    Patient recruitment rates correspond with Introgen's expectations as per
     the study designs.

PPD Development will review all timelines during the study and should any
situation arise that may compromise these timelines, PPD Development, with
Introgen's consent, may revise them or take further actions as necessary to
successfully complete the study to Introgen's satisfaction.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 31
<PAGE>
                                                               Project Addendum
--------------------------------------------------------------------------------

                             STATEMENT OF SERVICES

The following lists the specific responsibilities assigned to Introgen (x) or
PPD (x).
<Table>
<Caption>
                    ACTIVITY                              INTROGEN             PPD
                                                                           DEVELOPMENT
<S>                                                      <C>              <C>
STUDY SET-UP
A.   REGULATORY AFFAIRS
1.   Prepare Core Dossier                                   [*]                 [*]
                                                            [*]                 [*]
2.   Prepare, review and submit appropriate country         [*]                 [*]
     specific filings                                       [*]                 [*]
3.   Prepare Investigator Brochure                          [*]                 [*]
B.   STUDY DOCUMENTS
1.   Write and Approve Protocol                             [*]                 [*]
2.   Translate Protocol into appropriate languages          [*]                 [*]
     when necessary                                         [*]                 [*]
3.   Prepare template informed consent                      [*]                 [*]
4.   Translate informed consent into appropriate
     local languages                                        [*]                 [*]
5.   Provide specifications for CRF design                  [*]                 [*]
6.   Design CRF                                             [*]                 [*]
7.   Review CRF                                             [*]                 [*]
8.   Print and bind CRF                                     [*]                 [*]
9.   Write CRF instruction guide                            [*]                 [*]
10.  Distribute CRF to sites                                [*]                 [*]
C.   SITE IDENTIFICATION AND QUALIFICATION
1.   Develop list of additional potential sites             [*]                 [*]
                                                            [*]                 [*]
2.   Conduct pre-study qualification visits                 [*]                 [*]
3.   Negotiate investigator grants                          [*]                 [*]
4.   Administer investigator payments                       [*]                 [*]
5.   Prepare indemnity/liability statement                  [*]                 [*]
D.   RANDOMISATION
1.   Provide randomisation schedule                         [*]                 [*]
2.   Arrange for provision of randomisation materials       [*]                 [*]
E.   CENTRAL LABORATORY
1.   Identify central laboratory if applicable              [*]                 [*]
2.   Contract with central laboratory                       [*]                 [*]
3.   Resolve issues with central laboratory                 [*]                 [*]
4.   Administer payments to central laboratory              [*]                 [*]
F.   CLINICAL TRIAL SUPPLY MANAGEMENT
1.   Supply, package and label study drug                   [*]                 [*]
2.   Secondary labeling                                     [*]                 [*]
3.   Distribute study drug to sites                         [*]                 [*]
4.   Perform post-study drug accountability                 [*]                 [*]
5.   Return unused study drug to sponsor                    [*]                 [*]
6.   Distribute miscellaneous clinical supplies to site     [*]                 [*]

</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 32
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

<Table>
  <S>                                                        <C>          <C>
    G.   INVESTIGATOR MEETING
    1.   Organise and conduct investigator meeting            [*]               [*]
    2.   Prepare start-up information binders                 [*]               [*]
    3.   Approve start-up information binders                 [*]               [*]
    4.   Attend investigator meeting                          [*]               [*]
    5.   Present at investigator meeting                      [*]               [*]
    H.   ETHICS COMMITTEE APPROVAL AND SITE INITIATION
    1 .   Collect essential documents                         [*]               [*]
    2.   Obtain IEC approval                                  [*]               [*]
                                                              [*]               [*]
    3.   Conduct site initiation/hand-over visits             [*]               [*]
    4.   Provide training of site personnel                   [*]               [*]
    STUDY CONDUCT
    I.   ON-SITE MONITORING
    1.   Conduct interim on-site visits                       [*]               [*]
    2.   Review and verify available source documentation
    on all CRFs                                               [*]               [*]
    3.   Obtain corrections to all CRFs/query resolution      [*]               [*]
    4.   Review drug records                                  [*]               [*]
    5.   Verify investigators compliance with protocol
    and regulatory requirements                               [*]               [*]
    6.   Maintain training of personnel at study sites        [*]               [*]
    J.   SITE MANAGEMENT
    1.   Maintain phone log of clinical questions             [*]               [*]
    2.   Maintain phone log of questions regarding
    CRFs/logistics                                            [*]               [*]
    3.   Control of CRFs - log, track and archive             [*]               [*]
    4.   Make regular contact with site between visits        [*]               [*]
    K.   PROJECT MANAGEMENT
    1.   Provide regular updates to Sponsor via RTMS          [*]               [*]
    2.   Develop/maintain protocol deviation database         [*]               [*]
    3.   Provide on-going project team training               [*]               [*]
    4.   Review investigator payments                         [*]               [*]
    5.   Administer investigator payments                     [*]               [*]
    6.   Participate in client meetings                       [*]               [*]
    7.   Participate in team meetings                         [*]               [*]
    8.   Participate in conference calls                      [*]               [*]
    L.   MEDICAL MONITORING AND PHARMACOVIGILANCE
    1.   Conduct all Pharmacovigilance*                       [*]               [*]
    2.   Perform serious adverse event investigation          [*]               [*]
    3.   Write SAE patient narratives                         [*]               [*]
    M.   SITE CLOSE-OUT
    1.   Conduct study close-out visits                       [*]               [*]
    QUALITY ASSURANCE
    1.   In-house file audits                                 [*]               [*]
    2.   Study site audits                                    [*]               [*]

</Table>

* - Time and material rates are included in the grids below but will be
discussed in the Consulting Agreement.

** - Full specifications to follow in a contract modification.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 33
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                  EXHIBIT A.2

                                 [*] REGULATORY

     Personnel.   The Services shall be performed by PPD under the direction of
[*] and [*] or such other employee acceptable to Introgen as PPD may from time
to time designate.

     This service will be performed on a Time and Materials basis.

<Table>
                              STATEMENT OF SEVICES

<S>                                          <C>                 <C>
STUDY SET-UP                                   INTROGEN              PPD
REGULATORY AFFAIRS
1. Prepare Core Dossier                          [*]                  [*]
2. Prepare, review and submit appropriate
   country specific filings                      [*]                  [*]
3. Prepare Investigator Brochure                 [*]                  [*]
ETHICS COMMITTEE APPROVAL AND SITE INITIATION

1. Collect essential documents                   [*]                  [*]
2. Obtain IEC approval                           [*]                  [*]
4. Conduct hand-over visits at Introgen
   affiliate HQ                                  [*]                  [*]
5. Conduct additional set up visits to ensure
   maximized recruitment at site.*               [*]                  [*]

*Additional visits should be approved by
 Introgen in advance

</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 34
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                  EXHIBIT A.3

                                 [*] REGULATORY

     Introgen agrees to engage PPD to provide consulting services as described
in the Scope of Work listed below, and PPD agrees to provide such services.

     PPD agrees to comply with all regulations, laws and Introgen policies
applicable to the services to be performed under this Agreement, including
without limitation Introgen's Business Conduct Policy, which is enclosed for
reference. Further, PPD shall inform any of its employees providing services to
or on behalf of Introgen that they must abide by such regulations, laws and
policies and PPD shall obtain their written agreement to comply.

     This Regulatory component shall commence as of [*], and shall continue
through [*], unless further extended in writing.

     Introgen shall pay PPD as follows for professional fees:

     Regulatory Administrative Assistant     [*]
     Regulatory Affairs Specialist           [*]
     Manager, Regulatory Affairs             [*]
     Associate Director, Regulatory          [*]
     Director, Regulatory Affairs            [*]

     Said billing rates of PPD shall be in effect for the [*] first set forth
herein and shall be subject to change on a [*] basis.

     Fees for services for the duration of this agreement will be billed on a
time and materials basis and are not expected to exceed [*] (based on original
contract of [*] plus an additional [*] covered in an amendment with an effective
date of [*].

     In addition, Introgen shall reimburse PPD for actual expenses of pre
approved air travel (not in excess of the fares for air journeys reimbursed to
employees of Introgen), car fare (if for a personal car, not in excess of the
per mile rate reimbursed to employees of Introgen), and living expenses
reasonably incurred for travel necessary in connection with the performance of
the PPD's services and for reasonable out-of-pocket expenses such as telephone,
facsimile and reproduction expenses. Any expenses other than nominal out-of-
pocket expenses must be approved in advance by Introgen. At the end of [*]
during the existence of this Agreement, PPD shall submit an itemized list of his
expenses, if any, for the month, together with adequate documentation, and the
Introgen shall remit his fee and reimbursed expenses within [*] days thereafter.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 35
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                 Scope of Work

Under this agreement, PPD will act as the official correspondent to the FDA for
BB-IND 6165 and BB-IND 6026, and perform IND maintenance for these INDs
including those activities under 21 CFR 312.30, 312.31, 312.32, 312.33, 312.40,
312.47, and 312.50. Both paper and electronic copies of all regulatory
correspondence and submissions to the FDA will be provided to Introgen. PPD will
attend team meetings and may perform  additional tasks, at the written request
of Introgen, on an as needed basis.

In addition, PPD will prepare and submit site documents and report serious
adverse events to the NIH. Other submissions to the NIH, including points-to-
consider document's, and annual reports will also be prepared by Introgen. Both
paper and electronic copies of all correspondence and submissions to the NIH
will be provided to Introgen.

--------------------------------------------------------------------------------
                                                                         Page 36
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                  EXHIBIT A.4

                          IVRS PROJECT SPECIFICATIONS

The following are assumptions that PPD has used to calculate our cost proposal.
Should any of these assumptions change, PPD reserve the right to review the
budget and make any relevant amendments if appropriate.

<Table>

<S>                                  <C>            <C>
Protocol Number                         [*]            [*]

Number of Randomized Patients           [*]            [*]

Participating Countries/Sites           [*]            [*]

Language of Script and Prompt           [*]            [*]

Language of IVRS system                 [*]            [*]
& Randomization Notification

Number of Users                         [*]            [*]

Enrolment Period                        [*]            [*]

Number of Treatment Groups              [*]            [*]

Level of Support                        [*]            [*]

</Table>

[*]

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 37

<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                        EXHIBIT A.5

* MEDICAL AFFAIRS AND PHARMACOVIGILANCE (MA/PVG)

The following PPD Medical Affairs/Pharmacovigilance (MA/PVG) services and costs
are based on the information available to date. We have assumed additional
discussions may be required to finalize the specific activities needed for this
project.

Investigator sites will report serious adverse events (SAEs) to PPD's MA/PVG
group. Introgen's physician will be responsible for medical review of SAEs and
consulting with investigator sites and project team members. PPD will notify
Introgen of SAE's within one business day of receipt of SAE report. Introgen
will be responsible for providing the final causality/reportability assessment.
The MA/PVG group will obtain requested SAE follow-up information from
investigator sites, and will work in concert with the clinical project team to
resolve SAE related queries prior to the final clinical database lock.

Each SAE will be billed on a per event basis of [*] per SAE (subject to a [*]
inflation increase each year). SAE's which are reported to PPD, processed, and
subsequently downgraded to "not serious" will be included in the total number
of SAEs and billed accordingly.

Costs associated with narrative production, the set-up and maintenance of a SAE
database utilizing Clintrace(TM) software, the participation of a PPD
Development physician in an investigator meeting, MA/PVG review of lab data, or
AE listing and coding review are not included in this proposal. If Introgen
request PPD manage these tasks, cost can be provided under separate cover.

The MA/PVG group will submit to Introgen on a routine basis a SAE tracking
report which contains a listing of all SAEs received and the current status of
those SAEs. Upon request, any additional reports will be discussed with
Introgen and the costs for those reports submitted under separate cover.

PPD will be responsible for the submission of expedited safety reports to the
appropriate regulatory agencies. Each submission will be billed at [*] for
submission to the first country and [*] for each subsequent country.

All translation expenses (verbal or written) will be considered pass through
costs and billed accordingly.

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 38
<PAGE>
                                                               Project Addendum
--------------------------------------------------------------------------------

Actual costs to provide MA/PVG services will depend upon the nature, extent and
frequency of FDA inquiries regarding the safety reports as well as the extent
and frequency of document revisions requested by Introgen. For this reason,
MA/PVG costs provided within this budget may need to be negotiated on an annual
basis. Additionally, extensive follow-up requested by the Introgen or regulatory
agencies beyond that included in this proposal will be billed at time and
materials.

<Table>

<S>                                                    <C>              <C>
   TASK LIST                                            INTROGEN          PPD
V. SAFETY (MEDICAL AFFAIRS/PHARMACOVIGILANCE)
1. Receive and process SAEs from investigator sites.      [*]             [*]
2. Medically review SAE reports and final preliminary     [*]             [*]
   causality assessment statements/reportability
3. Maintain 24-hour Phone Line for reporting SAEs         [*]             [*]
4. Provide medical consultation to investigator sites     [*]             [*]
   and project team (24-hour Medical coverage)
5. Write SAE narratives                                   [*]             [*]
6. Submit expedited safety reports to appropriate         [*]             [*]
   regulatory agencies.
7. Maintain SAE database                                  [*]             [*]

</Table>

ALL TRAVEL IS PASS-THROUGH

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 39

<PAGE>

                                                                Project Addendum
--------------------------------------------------------------------------------

                                   EXHIBIT B
                                   [*] COSTS
                                      T301

<Table>
<S>                                          <C>                   <C>                 <C>           <C>            <C>
                 ASSUMPTIONS                     UNIT               COST PER UNIT       COST TYPE      ESTIMATED      SUB-TOTAL
UNIT#                  UNIT LABEL                                                                     TOTAL UNITS
     [*]
[*]                  [*]                          [*]                     [*]              [*]             [*]            [*]

                 ASSUMPTIONS                     UNIT               COST PER UNIT       COST TYPE      ESTIMATED      SUB-TOTAL
UNIT#                  UNIT LABEL                                                                     TOTAL UNITS

[*]                  [*]                          [*]                     [*]              [*]             [*]            [*]

</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 40
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

[*]
---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 41
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------
[*]
---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 42
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                    [*] COSTS
                                      T302
<Table>
<Caption>

                 ASSUMPTIONS                     UNIT               COST PER UNIT       COST TYPE      ESTIMATED      SUB-TOTAL
UNIT#                  UNIT LABEL                                                                     TOTAL UNITS
<S>                                            <C>                    <C>               <C>            <C>            <C>
                  [*]
[*]                                               [*]                   [*]                [*]            [*]            [*]
</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 43
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

<Table>
    <S>                                         <C>                     <C>          <C>        <C>      <C>
[*]
</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 44

<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

<Table>

<S>                                          <C>                   <C>                 <C>           <C>            <C>
[*]
</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 45
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                  [*] COSTS
                                      T301

<Table>
<S>                                                <C>                <C>                 <C>           <C>            <C>
                 ASSUMPTIONS                          UNIT             COST PER UNIT       COST TYPE      ESTIMATED     SUB-TOTAL
UNIT#                  UNIT LABEL                                                                        TOTAL UNITS

[*]                   [*]                              [*]                 [*]               [*]             [*]           [*]
</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 46
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

<Table>

Unit #              UNIT LABEL
    <S>                                <C>                           <C>             <C>           <C>        <C>
     [*]
</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 47
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------
                                   [*] COSTS
                                      T302

<Table>
<S>                                                <C>                   <C>                 <C>           <C>            <C>
                 ASSUMPTIONS                          UNIT               COST PER UNIT       COST TYPE      ESTIMATED     SUB-TOTAL
UNIT#                  UNIT LABEL                                                                          TOTAL UNITS
[*]                 [*]                               [*]                      [*]              [*]            [*]             [*]

     TOTAL CLINICAL DIRECT COSTS
UNIT#                  UNIT LABEL
[*]                 [*]                               [*]                      [*]              [*]            [*]             [*]
</Table>

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------

                                                                         PAGE 48
<PAGE>
                                                              Project Addendum
--------------------------------------------------------------------------------

                                   UNIT LABEL

   [*]
---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 49
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                        EXHIBIT C

Milestone Descriptions:

[*]

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 50

<PAGE>
                                                               Project Addendum
-------------------------------------------------------------------------------

                                   EXHIBIT D

                                      [*]

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 51

<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                      [*]

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                        Page 52
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                      [*]

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 53
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                      [*]

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 54

<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                      [*]

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 55

<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                      [*]

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 56
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                      [*]

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 57
<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                      [*]

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                        Page 58

<PAGE>
                                                                Project Addendum
--------------------------------------------------------------------------------

                                      [*]

---------
* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to
  the omitted portions.

--------------------------------------------------------------------------------
                                                                         Page 59<PAGE>
                                                                  EXHIBIT 10.7.1

                    AMENDED AND RESTATED EMPLOYMENT AGREEMENT

         THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this "Agreement") is
entered into as of December 26, 2001, between Home Interiors & Gifts, Inc., a
Texas corporation (together with its successors, the "Company"), and Christina
L. Carter Urschel ("Employee"), and amends and restates that certain Executive
Employment Agreement dated as of June 4, 1998 (the "Original Agreement"),
between the Company and Employee, pursuant to which Employee serves as President
of the Company.

         WHEREAS, the Company and Employee desire that Executive continue to
serve the Company in the capacities more particularly described below.

         NOW, THEREFORE, in consideration of the foregoing premises, the mutual
promises contained herein and of other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto
hereby agree as follows:

         1. Definitions.

                  "Accrued Benefits" means (i) all salary earned or accrued
         through the date the Employee's employment is terminated; (ii)
         reimbursement for any and all monies advanced in connection with the
         Employee's employment for reasonable expenses incurred by the Employee
         in accordance with Section 4(c) through the date the Employee's
         employment is terminated and (iii) all other payments and benefits to
         which the Employee or the Employee's family or other beneficiaries may
         be entitled under the terms of any applicable compensation arrangement,
         benefit plan, program or policy of the Company, including any
         compensation previously deferred by the Employee (together with any
         accrued earnings thereon) and not yet paid by the Company and any
         earned and accrued, but unused vacation pay, in each case through the
         Date of Termination.

                  "Act" shall mean the Securities Exchange Act of 1934, as
         amended.

                  "Affiliate" shall have the meaning given such term in Rule
         12b-2 of the Act.

                  "Base Salary" has the meaning set forth in Section 4(a).

                  "Board" shall mean the board of directors of the Company.

                  "Cause" shall mean (i) the Employee's conviction of any
         felony, unless the Board reasonably determines that the Employee's
         conviction of such felony does not materially affect the Employee's
         business reputation or significantly impair the Employee's ability to
         carry out her duties under this Agreement (provided the Board shall
         have no obligation to make such determination); (ii) the Employee's
         willful and material breach of her obligations under this Agreement, or
         (iii) the Employee's dishonesty or gross misconduct in connection with
         her employment hereunder which results in material damage to the
         Company's business. Notwithstanding the above, the occurrence of the
         event specified in clause (ii) above shall not constitute Cause unless
         the Employee fails to cure such event within ten (10) days after
         receipt from the Company of the Notice of Termination (as defined in
         Section 5(e) below).

                  "Change of Control" shall mean the first to occur of the
         following events: (1) the Company is acquired or becomes controlled by
         any Person or group of Persons, other than by any member of the HMC
         Group (as hereinafter defined); (2) Hicks, Muse, Tate & Furst
         Incorporated

<PAGE>

         or any of its Affiliates, including without limitation HM/RB Partners,
         L.P., a Delaware limited partnership, or its or their respective
         partners, employees, officers and directors (and members of their
         respective families and trusts for the primary benefit of such family
         members) (collectively, the "HMC Group") shall cease to have the power,
         directly or indirectly, to vote or direct the voting of securities
         having a majority of the ordinary voting power for the election of
         directors of the Company; or (3) the shareholders of the Company
         approve a complete liquidation or dissolution of the Company; provided
         that the occurrence of an event described in (1) or (2) above shall not
         be deemed a Change of Control if (a) prior to the consummation of an
         Initial Public Offering (i) the HMC Group otherwise has the right,
         directly or indirectly, to designate (and does so designate) a majority
         of the Board or (ii) the HMC Group, together with members of management
         of the Company, directly or indirectly, own of record and beneficially
         an amount of common stock of the Company equal to at least fifty
         percent (50%) of the amount of common stock of the Company (adjusted
         for stock splits, stock dividends and other similar events on an
         equitable basis) directly or indirectly owned by the HMC Group,
         together with management of the Company, of record and beneficially as
         of the date of this Agreement and such ownership by the HMC Group,
         together with members of management of the Company, represents the
         largest single block of voting securities of the Company held by any
         Person or group of Persons (within the meaning of Section 13(d) of the
         Act), or (b) after the consummation of an Initial Public Offering, and
         for any reason whatever, (i) no Person or group of Persons, excluding
         the HMC Group, shall become the beneficial owner, directly or
         indirectly, of more than the greater of (x) fifteen percent (15%) of
         the voting shares of the Company then outstanding and (y) the
         percentage of the then outstanding voting stock of the Company directly
         or indirectly owned by the HMC Group, together with members of
         management of the Company; and (ii) the Board shall consist of a
         majority of Continuing Directors. For the purposes of this definition,
         the term "the Company" shall include any successor to the Company.

                  "Continuing Directors" shall mean the directors of the Company
         on the date of this Agreement and each director appointed subsequent to
         the date of this Agreement, if, in each case, such other director's
         nomination for election to the Board, as applicable, is recommended by
         a majority of the directors at the time of such election or such
         director receives the vote of the HMC Group in his or her election by
         the shareholders.

                  "Control" (including the correlative terms "Controlled by" and
         "Controlling") shall mean the possession, directly or indirectly, of
         the power to direct, or to cause the direction of, the management and
         policies of a Person, whether through ownership of voting securities,
         by contract or otherwise.

                  "Employment Date" has the meaning set forth in Section 2.

                  "Employment Period" shall mean the period during which the
         Employee is employed by the Company.

                  "Good Reason" shall mean (i) any material breach by the
         Company of this Agreement, the Option Agreement, or the Shareholders
         Agreement (for so long as Employee is subject thereto) or the failure
         of the Employee to be a director of the Company for any reason (other
         than death, Permanent Disability, voluntary resignation or termination
         of employment for Cause); and (ii) a change, without the Employee's
         written consent, in the specified tasks Employee is to perform
         hereunder or of more than twenty-five (25) miles in the office or
         location where the Employee is based. Notwithstanding the above, the
         occurrence of any of the events described above will not constitute
         Good Reason unless the Company fails to cure any such event within

                                       2
<PAGE>

         ten (10) days after receipt from the Employee of the Notice of
         Termination (as defined in Section 5(e) below).

                  "Permanent Disability" shall mean the inability of the
         Employee to discharge her duties hereunder for a period of six (6)
         consecutive months, or for a total of six (6) months in any twelve (12)
         month period, by reason of physical or mental illness, injury or
         incapacity.

                  "Person" shall mean any "person," within the meaning of
         Sections 13(d) and 14(d) of the Act, including a "group" as therein
         defined.

                  "Shareholders Agreement" shall mean that certain Shareholders
         Agreement, dated as of June 4, 1998, among the Company and the
         securityholders of the Company listed on the signature pages thereof.

                  "Subsidiary" shall mean, with respect to any Person, any other
         Person of which such first Person owns the majority of the economic
         interest in such Person or owns or has the power to vote, directly or
         indirectly, securities representing a majority of the votes ordinarily
         entitled to be cast for the election of directors or other governing
         Persons.

         2. Term of Employment. Unless earlier terminated in accordance with the
terms of this Agreement, the Employment Period shall commence on the date hereof
(the "Employment Date") and shall end on first anniversary of the Employment
Date; provided, however, that such Employment Period shall be extended for
successive terms of one (1) year each unless either party advises the other in
good faith, at least 120 days prior to the end of the initial term or annual
extension, as the case may be, that it will not agree to extend this Agreement.

         3. Duties. During the Employment Period, the Employee (i) shall serve
as Vice Chairman of the Board and as National Spokesperson for the Company; (ii)
shall report directly to the Chief Executive Officer of the Company; (iii) shall
provide consulting services to the Chief Executive Officer of the Company as
Employee and the Chief Executive Officer may reasonably agree from time to time
(which agreement may include additional compensation to Employee); (iv) shall
participate in each of the following (A) the Company's annual Seminar, (B) the
Company's annual Director's Conference, and (C) the Company's annual Upper Level
Director's Fall Retreat; (v) shall participate in the development of the
Pocketful of Hope Charities; and (vi) shall devote reasonable time to perform
faithfully and efficiently the responsibilities assigned to Employee hereunder.

         4. Compensation. During the Employment Period, the Employee shall be
compensated as follows:

                  (a) the Employee shall receive an annual salary (pro rata for
         any partial year) equal to $100,000 (the "Base Salary"), which Base
         Salary shall be payable in equal monthly installments and shall be
         subject to appropriate increase, as determined by the sole discretion
         of the Board;

                  (b) the Employee shall be entitled a bonus, in such amount, if
         any, as may be determined by the Board in its sole discretion;

                  (c) the Employee shall be reimbursed, at such intervals and in
         accordance with such Company policies regarding proper documentation as
         may be in effect from time to time, for any and all reasonable business
         expenses incurred by her in the business interests of the Company,
         including but not limited to travel and wardrobe expenses;

                                       3
<PAGE>

                  (d) the Employee shall be entitled to participate in all
         incentive, savings, retirement and death benefit plans, practices,
         policies and programs on a basis no less favorable than that basis
         available to senior executives of the Company as determined by the
         Board from time to time; provided, however, that in no event shall the
         Employee be entitled to participate in the Executive Bonus Plan;

                  (e) the Employee and/or the Employee's family, as the case may
         be, shall be eligible for participation in and shall receive all
         benefits under welfare benefit plans, practices, policies and programs
         generally provided by the Company to senior executives of the Company
         (including, without limitation, medical, prescription, dental,
         disability, salary continuance, employee life, group life, accidental
         death and travel accident insurance plans and programs), in each case
         at the most favorable level of participation and providing the highest
         levels of benefits available to them; and

                  (f) the Employee shall be entitled to receive (in addition to
         the benefits described above) such perquisites and fringe benefits
         appertaining to Employee's position in accordance with any practice
         established by the Board, including without limitation, air travel
         arrangements consistent with the policies and practices in effect
         during the one (1) year prior to the date of this Agreement.

         5. Termination of Employment.

                  (a) Permanent Disability. The Company may terminate the
         Employee's employment because of a Permanent Disability by first giving
         Employee written notice of the Company's intention to terminate such
         employment.

                  (b) Voluntary Termination by Employee. Notwithstanding
         anything in this Agreement to the contrary the Employee may, upon not
         less than thirty (30) days written notice to the Company, voluntarily
         terminate employment for any reason (provided that any termination by
         the Employee pursuant to Section 5(d) on account of Good Reason shall
         not be treated as a voluntary termination under this Section 5(b)).

                  (c) Termination by the Company. The Company at any time may
         terminate the Employee's employment for Cause or without Cause.

                  (d) Good Reason. The Employee at any time may terminate her
         employment for Good Reason.

                  (e) Notice of Termination. Any termination by the Company for
         Cause or by the Employee for Good Reason shall be communicated by a
         Notice of Termination to the other party hereto given in accordance
         with Section 17. For purposes of this Agreement, a "Notice of
         Termination" means a written notice given, in the case of a termination
         for Cause, within one hundred eighty (180) days of the Company's having
         actual knowledge of the events giving rise to such termination, and in
         the case of a termination for Good Reason, within one hundred eighty
         (180) days of the Employee's having actual knowledge of the events
         giving rise to such termination. The Notice of Termination shall: (i)
         indicate the specific termination provision in this Agreement relied
         upon; (ii) set forth in reasonable detail the facts and circumstances
         claimed to provide a basis for termination of the Employee's employment
         under the provision so indicated; and (iii) if the termination date is
         other than the date of receipt of such notice, specify the termination
         date of this Agreement (which date shall be no more than fifteen (15)
         days after the giving of such notice). The failure by the Employee or
         the Company to set forth in the Notice

                                       4
<PAGE>

         of Termination any fact or circumstance which contributes to a showing
         of Good Reason or Cause, as applicable, shall not waive any right of
         the Employee hereunder or preclude the Employee from asserting such
         fact or circumstance in enforcing her rights hereunder. In addition, in
         the event the Company determines to terminate the Employee's employment
         without Cause, the Company shall deliver to the Employee written
         notification thereof on a date not later than the Date of Termination.

                  (f) Date of Termination. For the purpose of this Agreement,
         the term "Date of Termination" means: (i) in the case of a termination
         for which a Notice of Termination is required, the date of receipt of
         such Notice of Termination or, if later, the date specified therein, as
         the case may be; and (ii) in all other cases, the actual date on which
         the Employee's employment terminates.

         6. Obligations of the Company Upon Termination. Upon termination of the
Employee's employment with the Company, the Company shall have the following
obligations:

                  (a) Death. If the Employee's employment is terminated by
         reason of the Employee's death, all Accrued Expenses shall be paid to
         the Employee, her beneficiaries, or her estate, as applicable, in a
         lump sum in cash within thirty (30) days after the Date of Termination.
         In addition, the Employee's family shall be entitled to receive
         benefits generally available to the surviving families of senior
         executives of the Company.

                  (b) Permanent Disability. If the Employee's employment is
         terminated by reason of the Employee's Permanent Disability, the
         Employee, and the Employee's spouse, shall be entitled to continue to
         participate in or be covered under the Company's health and life
         insurance benefit plans generally applicable to senior executives of
         the Company or, at the Company's option, to receive equivalent benefits
         by alternate means, at least equal to such health and life insurance
         benefits. Unless otherwise directed by the Employee, the Employee shall
         also be paid all Accrued Benefits in a lump sum in cash within thirty
         (30) days after the Date of Termination. In addition, the Executive
         shall receive severance pay from the Company in an amount equal to one
         hundred percent (100%) of the total Base Salary and Annual Bonus, if
         any, received by the Executive with respect to the fiscal year
         immediately prior to the fiscal year in which such Date of Termination
         occurs; provided, however, that the Company shall not be obligated to
         make such severance payment to the extent that such severance payment
         reduces the disability benefits to which the Executive is entitled from
         an insurer by an equal or greater amount. Such severance payment is to
         be made within thirty (30) days after the Date of Termination.

                  (c) Termination by the Company for Cause and Voluntary
         Termination by Employee. If the Employee's employment is terminated for
         Cause or voluntarily terminated by the Employee (other than for Good
         Reason), the Company shall pay the Employee the Accrued Benefits in a
         lump sum in cash within thirty (30) days after the Date of Termination.

                  (d) Other Termination of Employment. If the Company terminates
         the Employee's employment other than for Cause or Permanent Disability,
         or the Employee terminates her employment for Good Reason, the Company
         shall pay or provide the Employee the following:

                           (A) Cash Payment. The Company shall pay to the
                  Employee (i) a lump sum in cash within 30 days after the Date
                  of Termination an amount equal to all Accrued Benefits, (ii)
                  an amount equal to the unpaid portion of Employee's Base
                  Salary through the end of the current calendar year payable in
                  accordance with the Company's customary payroll practices,
                  plus (iii) a severance payment in an amount equal to one
                  hundred

                                       5
<PAGE>

                  percent (100%) of the total Base Salary and Annual Bonus, if
                  any, received by the Executive with respect to the fiscal year
                  immediately prior to the fiscal year in which such Date of
                  Termination occurs; and

                           (B) Other Benefits Continuation. The Company shall
                  provide for the continued participation of the Employee, and
                  her spouse, as the case may be, until June 4, 2003, in the
                  Company's health and life insurance benefit plans generally
                  applicable to senior executives of the Company. In lieu of
                  continued participation in any such medical and life insurance
                  programs, the Employee may elect by written notice delivered
                  to the Company prior to the Date of Termination to receive an
                  amount equal to the annual cost to the Company (based on
                  premium rates) of providing such coverage.

                  (e) Any amounts payable to the Employee pursuant to this
         Section 6 shall be considered severance payments and be in full and
         complete satisfaction of the obligations of the Company to the Employee
         in connection with the termination of the Employee.

         7. Applicability of Section 280G of the Code.

                  (a) Limitation on Severance Pay and Other Benefits. The
         provisions of this Section 7 are restated from the Original Agreement
         for which approval was received by a separate vote of the Company's
         shareholders in accordance with Section 7(g) of the Original Agreement.

                  (b) Tax Reimbursement Payment. If the amount or benefit paid
         or distributed to the Executive by the Company or any Person that is an
         Affiliate of the Company, whether pursuant to this Agreement or
         otherwise with respect to employment by the Company after the
         Employment Date (collectively, the "Covered Payments"), is or becomes
         subject to the tax imposed under Section 4999 of the Code or any
         similar tax that may hereafter be imposed (the "Excise Tax") and if
         this Agreement has been approved by a separate vote of the Company's
         shareholders in accordance with Section 7(g) below, the Company shall
         pay to the Executive, at the time specified in Section 7(f) below, the
         Tax Reimbursement Payment (as defined below). The Tax Reimbursement
         Payment is defined as an amount, which when added to the Covered
         Payments and reduced by any Excise Tax on the Covered Payments and any
         federal, state and local income tax and Excise Tax on the Tax
         Reimbursement Payment provided for by this Agreement (but without
         reduction for any federal, state and local income or employment tax on
         such Covered Payments), shall be equal to the sum of (i) the amount of
         the Covered Payments; and (ii) an amount equal to the product of any
         otherwise permitted deductions disallowed for federal, state or local
         income tax purposes as a result of the inclusion of the Tax
         Reimbursement Payment in the Executive's adjusted gross income and the
         applicable marginal rate of federal, state or local income taxation if
         the Tax Reimbursement Payment had not been made, respectively, for the
         calendar year in which the Tax Reimbursement Payment is to be made.

                  (c) Determining Excise Tax. For purposes of determining
         whether any of the Covered Payments will be subject to the Excise Tax
         and the amount of such Excise Tax,

                           (i) such Covered Payments will be treated as
                  "parachute payments" within the meaning of Section 280G of the
                  Code, and all "parachute payments" in excess of the "base
                  amount" (as defined under Section 280G(b)(3) of the Code)
                  shall be treated as subject to the Excise Tax, to the extent
                  so determined in the opinion of the Company's independent
                  certified public accountants (the "Accountants"); and

                                       6
<PAGE>

                           (ii) the value of any non-cash benefits or any
                  deferred payment or benefit shall be determined by the
                  Accountants in accordance with the principles of Section 280G
                  of the Code.

                  (d) Applicable Tax Rates and Deductions. For purposes of
         determining the amount of the Tax Reimbursement Payment, the Executive
         shall be deemed:

                           (i) to pay federal income taxes at the highest
                  applicable marginal rate of federal income taxation for the
                  calendar year in which the Tax Reimbursement Payment is to be
                  made, except in connection with the determination of the Tax
                  Reimbursement Payment attributable to a disallowed deduction
                  under clause (ii) of the definition of Tax Reimbursement
                  Payment; and

                           (ii) to pay any applicable state and local income
                  taxes at the highest applicable marginal rate of taxation for
                  the calendar in which the Tax Reimbursement Payment is to be
                  made, net of the maximum reduction in federal income taxes
                  which could be obtained from the deduction of such state or
                  local taxes if paid in such year (determined without regard to
                  limitations on deductions based upon the amount of the
                  Executive's adjusted gross income).

                  (e) Subsequent Events. In the event that the Excise Tax is
         subsequently determined by the Accountants or the Internal Revenue
         Service to be less than the amount taken into account hereunder in
         calculating the Tax Reimbursement Payment made, the Executive shall
         repay to the Company, at the time that the amount of such reduction in
         the Excise Tax is finally determined, the portion of such prior Tax
         Reimbursement Payment that has been paid to the Executive or to
         federal, state or local tax authorities on the Executive's behalf and
         that would not have been paid if such Excise Tax had been applied in
         initially calculating such Tax Reimbursement Payment, plus interest on
         the amount of such repayment at the rate provided in Section
         1274(b)(2)(B) of the Code. Notwithstanding the foregoing provisions of
         this Section 7(e), in the event any portion of the Tax Reimbursement
         Payment to be refunded to the Company has been paid to any federal,
         state or local tax authority, repayment thereof shall not be required
         until actual refund or credit of such portion has been made to the
         Executive, and interest payable to the Company shall not exceed
         interest received or credited to the Executive by such tax authority
         for the period it held such portion. The Executive and the Company
         shall mutually agree upon the course of action to be pursued (and the
         method of allocating the expenses thereof) if the Executive's good
         faith claim for refund or credit is denied.

                  In the event that the Excise Tax is later determined by the
         Accountants to exceed the amount taken into account hereunder at the
         time the Tax Reimbursement Payment is made (including, but not limited
         to, by reason of any payment the existence or amount of which cannot be
         determined at the time of the Tax Reimbursement Payment in respect
         thereof) the Company shall make an additional Tax Reimbursement Payment
         of such excess (which Tax Reimbursement Payment shall include any
         interest or penalty payable with respect to such excess) at the time
         that the amount of such excess is finally determined.

                  The Company and the Executive each agrees to reasonably
         cooperate in good faith in the event of any reduction in payments or
         benefits pursuant to Section 7(a) or any Tax Reimbursement Payment
         pursuant to Section 7(b) to minimize the amount of such reduction or
         Tax Reimbursement Payment and to take such other actions under this
         Section 7 as may be necessary or required.

                                       7
<PAGE>

                  (f) Date of Payment. The portion of the Tax Reimbursement
         Payment attributable to a Covered Payment shall be paid to the
         Executive within ten (10) business days following the payment of the
         Covered Payment. If the amount of such Tax Reimbursement Payment (or
         portion thereof) is due, the Company shall pay to the Executive, an
         amount estimated in good faith by the Accountants to be the minimum
         amount of such Tax Reimbursement Payment and shall pay the remainder of
         such Tax Reimbursement Payment (which Tax Reimbursement Payment shall
         include interest at the rate provided in Section 1274(b)(2)(B) of the
         Code) as soon as the amount thereof can be determined, but in no event
         later than forty-five (45) calendar days after payment of the related
         Covered Payment. In the event that the amount of the estimated Tax
         Reimbursement Payment exceeds the amount subsequently determined to
         have been due, such excess shall be repaid or refunded pursuant to the
         provisions of Section 7(e) above.

         8. Non-Exclusivity of Rights. Nothing in this Agreement shall limit or
otherwise prejudice such rights as the Employee may have under any other
agreements with the Company, including, but not limited to stock option or
restricted stock agreements. Amounts which are vested benefits or which the
Employee is otherwise entitled to receive under any plan or program of the
Company at or subsequent to the Date of Termination shall be payable in
accordance with such plan or program.

         9. Full Settlement. The Company's obligation to make the payments
provided for in this Agreement and otherwise to perform its obligations
hereunder shall not be affected by any circumstances, including, without
limitation, any set-off, counterclaim, recoupment, defense or other right which
the Company may have against the Employee or others whether by reason of the
subsequent employment of the Employee or otherwise. In no event shall the
Employee be obligated to seek other employment by way of mitigation of the
amounts payable to the Employee under any of the provisions of this Agreement.

         10. Legal Fees and Expenses. The Company shall pay or cause to be paid
any and all reasonable attorneys' fees and expenses incurred by Employee in
connection with the preparation and negotiation of this Agreement promptly
following receipt of an invoice therefor (together with reasonable supporting
documentation) from Employee.

         11. Confidentiality; Return of Records. During and following the
Employee's employment by the Company, the Employee shall use commercially
reasonable efforts to hold in confidence and not directly or indirectly disclose
any confidential information or proprietary data of the Company or any of its
Subsidiaries, except to the extent authorized by the Board or required by any
court or administrative agency or legal process, other than to an employee of or
contractor with the Company or any of its Subsidiaries, or a Person to whom the
Employee in good faith believes disclosure is reasonably necessary or
appropriate in connection with the performance by the Employee of her duties as
an executive of the Company. In determining whether such disclosure is required,
Employee will be entitled to rely on the written advice of counsel provided to
the Company. Confidential information shall not include any information known
generally to the public or in the industry in which Company is engaged. All
records, files, documents and materials, or copies thereof, relating to the
Company's or any of its Subsidiaries', business which the Employee shall
prepare, or use, or come into contact with, shall be and remain the sole
property of the Company or any of its Subsidiaries, as the case may be, and
shall be promptly returned by the Employee to the Company or such Subsidiary (as
applicable) upon termination of the Employee's employment with the Company. The
Employee hereby acknowledges and agrees that damages will not be an adequate
remedy for the Employee's breach of any of her covenants contained in this
Section 11, and further agrees that the Company shall be entitled to obtain
appropriate injunctive and/or other equitable relief for any such breach,
without the posting of any bond or other security.

         12. Successors. The Company may assign its rights under this Agreement
to any successor to all or substantially all the assets of the Company, by
merger or otherwise, and may assign or encumber

                                       8
<PAGE>

this Agreement and its rights hereunder as security for indebtedness of the
Company. Any such assignment by the Company shall remain subject to the
Employee's rights under this Agreement, including without limitation, Section 5
and Section 6 hereof. The rights of the Employee under this Agreement may not be
assigned or encumbered by the Employee, voluntarily or involuntarily, during her
lifetime, and any such purported assignment shall be void ab initio. However,
all rights of the Employee under this Agreement shall inure to the benefit of
and be enforceable by the Employee's personal or legal representatives, estates,
executors, administrators, heirs and beneficiaries. All amounts payable to the
Employee hereunder shall be paid, in the event of the Employee's death, to the
Employee's estate, heirs or representatives.

         13. Third Parties. Except for the rights granted to the Company and its
Subsidiaries pursuant hereto (including, without limitation, pursuant to Section
10 hereof) and except as expressly set forth or referred to herein, nothing
herein expressed or implied is intended or shall be construed to confer upon or
give any Person other than the parties hereto and their successors and permitted
assigns any rights or remedies under or by reason of this Agreement.

         14. Enforcement. The provisions of this Agreement shall be regarded as
divisible, and if any of said provisions or any part thereof is declared invalid
or unenforceable by a court of competent jurisdiction, the validity and
enforceability of the remainder of such provisions or parts hereof and the
applicability thereof shall not be affected thereby.

         15. Amendment. This Agreement may not be amended or modified at any
time except by a written instrument approved by the Board, and executed by the
Company and the Employee; provided, however, that any attempted amendment or
modification without such approval and execution shall be null and void ab
initio and of no effect.

         16. Withholding. The Company shall be entitled to withhold from any
amounts to be paid to the Employee hereunder any federal, state, local, or
foreign withholding or other taxes or charges which it is from time to time
required to withhold. The Company shall be entitled to rely on an opinion of
counsel if any question as to the amount or requirement of any such withholding
shall arise.

         17. Governing Law. This Agreement and the rights and obligations
hereunder shall be governed by and construed in accordance with the laws of the
State of Texas, without regard to principles of conflicts of law of Texas or any
other jurisdiction.

         18. Notice. Notices given pursuant to this Agreement shall be in
writing and shall be deemed given when received and, if mailed, shall be mailed
by United States registered or certified mail, return receipt requested,
addressee only, postage prepaid:

         If to the Company:

                  Home Interiors & Gifts, Inc.
                  1649 Frankford Road West
                  Carrollton, Texas 75007
                  Attention: Chief Executive Officer

         If to the Employee:

                  Christina L. Carter Urschel
                  4923 Brookview Drive
                  Dallas, Texas 75220

                                       9
<PAGE>

         or to such other address as the party to be notified shall have given
to the other in accordance with the notice provisions set forth in this Section
17.

         19. No Waiver. No waiver by either party at any time of any breach by
the other party of, or compliance with, any condition or provision of this
Agreement to be performed by the other party shall be deemed a waiver of similar
or dissimilar provisions or conditions at any time.

         20. Headings. The headings contained herein are for reference only and
shall not affect the meaning or interpretation of any provision of this
Agreement.

         21. Resignation. Concurrently with the execution and delivery of this
Agreement, Employee is tendering her resignation as President of the Company in
the form attached hereto as Exhibit A.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       10
<PAGE>

         IN WITNESS WHEREOF, the parties have executed this Agreement in one or
more counterparts, each of which shall be deemed one and the same instrument, as
of the day and year first written above.

                                             HOME INTERIORS & GIFTS, INC.

                                             By:
                                                   -----------------------------
                                             Name:
                                                   -----------------------------
                                             Title:
                                                   -----------------------------

                                             EMPLOYEE:

                                             /s/ CHRISTINA L. CARTER URSCHEL
                                             -----------------------------------
                                             Christina L. Carter Urschel

                                       11
<PAGE>

                                                                       EXHIBIT A

                                   RESIGNATION

         In connection with her acceptance of the positions as National
Spokesperson and Vice Chairman, the undersigned, Christina L. Carter Urschel,
hereby tenders her resignation as the President of Home Interiors & Gifts, Inc.,
a Texas corporation, effective as of December 26, 2001.

                                                 /s/ CHRISTINA L. CARTER URSCHEL
                                                 -------------------------------
                                                 Christina L. Carter Urschel

                                       12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]